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Abstract 
 
The pathogenesis of hepatic encephalopathy (HE) in cirrhosis is multifactorial and 
the role of ammonia remains controversial. Experimental studies conducted in 
animal (rat) models of HE, in combination with pharmacological approaches, were 
used to test the hypothesis that during HE, chronic exposure to elevated ammonia 
concentrations alters cerebral oxygenation, compromises lactate transport between 
astrocytes and neurons, and impairs uptake of neurotransmitters. It was also 
hypothesised that HE impairs glymphatic clearance mechanisms, either as a cause 
or a consequence of the disease, which exacerbates the detrimental central nervous 
effects of the accumulated toxins. The results of the experiments described in this 
thesis suggest that in HE: a) ammonia compromises cerebral oxygenation, but does 
not affect cerebrovascular reactivity, b) ammonia mediates cortical hemichannel 
dysfunction and impairs channel-mediated lactate release, potentially interfering with 
the astrocyte-neuron lactate shuttle, c) hyperammonemia results in a significant 
increase in cortical extracellular glutamate concentration, which is exacerbated 
under hypoxic conditions, and d) efficacy of glymphatic clearance is affected in 
discrete regions of the brain, which aligns with specific cognitive/behavioral 
impairments. These findings provide the first evidence of a critical pathophysiological 
role of ammonia in inducing neuronal energy deficit in HE due to impaired cerebral 
oxygenation, compromised hemichannel-mediated lactate transport between 
astrocytes and neurons and affected glymphatic clearance. 
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Chapter 1: Background 
 
1.0  Introduction 
 
The liver is responsible for many bodily functions of complex organisms 
characterising its vital role in life. When liver failure occurs, severe complications 
arise making the understanding of the pathophysiology of liver disease critical. Liver 
failure is classified as acute (ALF) or chronic liver disease (CLD), while a new 
category has recently been introduced known as acute-on-chronic liver failure (Jalan 
et al., 2014). ALF is the acute liver injury (hepatocellular necrosis) occurring within 
hours up to 6 months after the onset of jaundice (O'Grady et al., 1993, Bosoi and 
Rose, 2013a). ALF is more frequently caused by drug intoxication and 
hepatotoxicity, with the main cause in the UK and the US being acetaminophen 
overdose. Moreover, acute viral hepatitis (A/B) and autoimmune hepatitis can also 
be responsible for ALF, while a large proportion of aetiologies are still to be identified 
(O'Grady et al., 1993, Bosoi and Rose, 2013a). On the other hand, CLD occurs due 
to a chronic deterioration of the liver function by a persistent, long-term hepatic 
insult. The time course of this disease is longer, 10-30 years, with the result of 
development of cirrhosis. This is mainly caused by chronic viral hepatitis, long term 
alcohol consumption as well as accumulation of fat deposits in the liver (non-
alcoholic fatty liver disease, non-alcoholic steatohepatitis) (Rosselli et al., 2013, 
Bosoi and Rose, 2013a). 
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1.1  Hepatic encephalopathy: Pathogenesis 
 
The liver and the brain interact greatly, with the most important function of the liver 
being the removal of toxic substances (including neurotoxins such as ammonia and 
manganese) from the blood (Butterworth, 2002). As a result, a dysfunction in the 
liver can easily disrupt the brain function and result in what we know as hepatic 
encephalopathy (HE). HE is defined as “brain dysfunction caused by liver 
insufficiency and/or porto-systemic shunting manifesting as a wide spectrum of 
neurological or psychiatric abnormalities ranging from subclinical alterations to 
coma” (American Association for the Study of Liver and European Association for the 
Study of the, 2014). The clinical symptoms, as indicated by the above definition, are 
widely variable extending from subtle impairment in mental state, fine motor and 
psychomotor functions to coma. The progression and development of HE is believed 
to occur due to various distinct pathophysiological mechanisms such as inflammation 
(Jalan et al., 2004b), oxidative stress (Bosoi and Rose, 2013b), impaired blood brain 
barrier (BBB) permeability (Haussinger et al., 2000), impaired energy metabolism of 
the brain (Rama Rao and Norenberg, 2012) and (the most common) the neurotoxic 
effects of high ammonia concentrations (Shawcross and Jalan, 2005). Some of 
these factors, summarised on Figure 1 will be further discussed in the following 
sections with more emphasis on the role of ammonia, as it has been the main focus 
of this project. 
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Figure 1: Factors contributing to the pathogenesis of HE. Factors contributing to the 
pathogenesis of HE with emphasis on the systemic effects of ammonia and inflammation 
developing due to liver disease. NO: nitric oxide; NH3: ammonia; NH4+: ammonium ions 
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1.1.1 Ammonia  
 
Ammonia is a ubiquitous by-product of nitrogen metabolism and several metabolic 
disorders may develop due to its accumulation (Burton, 2000, Hadjihambi et al., 
2014a). The primary source of ammonia production is the gut. This takes place in the 
enterocytes and the ammonia-generating intestinal bacteria through the enzyme 
phosphate-activated glutaminase (PAG), catalysing deamination of glutamine to 
glutamate (Kato et al., 1992). Most ammonia is normally detoxified by the liver 
through the urea cycle (Bosoi and Rose, 2013a, Cooper and Plum, 1987). Further 
metabolism takes place in a smaller scale in the muscles, heart, kidneys and the 
brain (Wakim-Fleming, 2011).   
 
Ammonia exists in equilibrium with the ionic (NH4+) and gas form (NH3), crossing all 
plasma membranes by passive diffusion. Neurons produce as much NH4+ as they do 
glutamate (both linked to the glutamate-glutamine cycle discussed later) (Schousboe 
et al., 2013, Lerchundi et al., 2015). Brain tissue ammonia increases within seconds 
of neuronal activity and it is quickly captured by astrocytes. Due to the similar ionic 
properties of NH4+ with potassium (K+), in terms of charge and diameter, NH4+ 
crosses biological membranes through K+ channels, as well as K+ cotransporters 
[sodium (Na+)/K+, H+/K+ ATPase and Na+-K+-Cl- cotransporters] (Moser, 1987, 
Nagaraja and Brookes, 1998) (Brookes, 2000, Marcaggi and Coles, 2001). Due to 
the permeability of ammonia across the BBB, toxic concentrations can easily be 
reached in the brain when systemic concentrations arise above normal (Bosoi and 
Rose, 2009).  Furthermore, ammonia can influence the passage of various branched 
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chain and aromatic amino acids which can eventually result in impaired serotonergic 
and glutametergic neurotransmission (Skowronska et al., 2012, Cauli et al., 2009).  
 
During liver disease, hyperammonemia develops due to urea cycle defects and 
increases in gut bacterial translocation (unknown mechanisms). Studies by Felipo et 
al. (Felipo and Butterworth, 2002a) have also shown that children with congenital 
urea cycle enzyme defects have a high serum ammonia concentration, which leads 
to severe neurological symptoms, seizure and coma if left untreated, resembling the 
symptoms of HE.  
 
The development of hyperammonemia in HE received considerable attention in the 
early 18th century with the experiments of Pavlov, Nencki and Zaleski using dogs that 
underwent portacaval fistula surgery, developing neuropsychiatric changes, with 
worsening of symptoms when the dogs were fed with meat (Hahn M, 1893). This led 
to the term “meat intoxication syndrome”. In 1991, direct evidence for the role of 
ammonia in the pathogenesis of HE was obtained by Lockwood et al., (Lockwood et 
al., 1991), with the use of radiolabeled nitrogen in positron emission tomography 
(PET) imaging studies of patients with severe liver disease and minimal HE (mHE) 
(Prakash and Mullen, 2010). Several studies since then have suggested that in ALF, 
the arterial ammonia concentration correlates with intracranial pressure (ICP), 
severity of clinical presentation and death by brain herniation (Jalan et al., 2004b, 
Clemmesen et al., 1999, Bernal et al., 2007, Bosoi and Rose, 2013a). On the other 
hand, in CLD (approximately 10% of the patients) direct correlation between 
ammonia and severity of HE is not consistently observed. Examples include 
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comatose patients with normal arterial ammonia concentrations (Nicolao et al., 2003, 
He Y, 2011), suggesting the involvement of other factors in the pathogenesis of HE.  
 
Despite the lack of correlation with severity of HE, elevated ammonia has detrimental 
consequences in the brain, such as depression of synaptic transmission (Cordoba et 
al., 2003, Butterworth, 2000). Furthermore, neurons exposed to elevated ammonia 
(or K+) levels, have increased intracellular chloride (Cl-) content, which can result in 
neuronal disinhibition (Benjamin et al., 1978, Dzhala et al., 2010). During health, the 
enzyme glutamine synthetase (GS), which is abundant in the liver, incorporates 
ammonia into glutamate (in equimolar concentrations), forming glutamine and 
consuming ATP. However, when liver failure occurs, this pathway is unavailable, and 
therefore other organs expressing GS such as muscles, kidney and brain, become 
the primary ammonia-detoxifying pathway (Rose, 2012, Olde Damink et al., 2009). 
Astrocytes are the only cells in the brain that express this enzyme. It is therefore 
believed that due to glutamine being an osmolite, its accumulation results in volume 
changes in astrocytes referred to as “swelling”, leading to cerebral oedema and 
increased ICP (Norenberg, 1977) (Haussinger et al., 2000).  
 
Ammonia also appears to have a direct effect on astrocytes. A decrease in glial 
fibrillary acidic protein (GFAP) (Sobel et al., 1981), glycogen, altered protein 
phosphorylation, cyclic adenosine monophosphate levels and impairment in uptake 
of K+, myo-inositol as well as calcium (Ca2+) has been reported. In vitro culture 
studies by Rama Rao et al., (Rama Rao et al., 2003) suggested that high 
concentrations of ammonia could increase the astrocytic expression of glucose 
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transporter 1 (GLUT-1) (Belanger et al., 2006) and aquaporin-4 (AQP4), the main 
water channel in the brain, two systems central to cerebral volume regulation 
(Nicchia et al., 2005). 
 
1.1.2 Inflammation  
 
The effects of increased ammonia alone cannot explain all of the neurological 
changes that characterize HE. In 2000, Rolando and his colleagues (Rolando et al., 
2000) suggested that in ALF patients, the presence of a systemic inflammatory 
response syndrome (SIRS), characterised by the abnormal regulation of cytokines, 
associated with manifestations such as high body temperature, heart rate, tachypnea 
and abnormal white blood cells, resulted in a poorer neurological outcome. Cerebral 
inflammation has been demonstrated to contribute to the development of HE 
(Butterworth, 2011, Jalan et al., 2004b) while the study of Shawcross et al., 
(Shawcross et al., 2004), indicated that inflammatory mediators, such as 
proinflammatory cytokines and nitric oxide (NO), worsens the neuropsychological 
effects of hyperammonemia in patients with cirrhosis. In this study, resolution of the 
inflammation was associated with improvement in the mental state, despite the same 
degree of liver dysfunction and plasma ammonia concentration, highlighting the 
importance of inflammation in the neuropsychological phenotype of HE. 
 
Furthermore, in ALF patients, serum proinflammatory cytokines have shown to be 
correlated with brain oedema and high ICP (Gupta et al., 2010, Jalan et al., 2004b). 
A similar phenotype has been reported in animal models of HE. In these animals, 
	 8	
hypothermia and antibiotic treatment indicated beneficial effects in brain oedema 
attenuation as well as decrease in serum and cerebral cytokines (Jiang et al., 2009b, 
Jiang et al., 2009a). Similarly, Bémeur et al., (Bemeur et al., 2010) demonstrated 
that brain oedema development was suppressed in interleukin-1 (IL-1) (IL-1β and IL-
1 receptor type 1) and tumor necrosis factor (TNF-α) knock-out (KO) ALF mice. The 
link between inflammation and brain oedema has also been observed in CLD 
(Montoliu et al., 2009) indicating serum proinflammatory cytokines TNF-α, IL-6 and 
IL-8 being higher in cirrhotic patients with mHE than those without HE, agreeing with 
the findings of Shawcross et al., (Shawcross et al., 2007).  
 
It is now clear that the systemic immune system communicates with the brain in 
response to infection and inflammation (Hosoi et al., 2002). The exact mechanism by 
which inflammation modulates the neuropsychological response to 
hyperammonemia is still unknown. Cytokines may modulate ammonia diffusion 
within the central nervous system (CNS) since the release of IL-6, TNF-α, and IL-1β 
during inflammation increases the BBB permeability (de Vries et al., 1996), as well 
as ammonia diffusion across astrocytes (Duchini et al., 1996). Finally, the astrocytic 
release of TNF-α and glutamate further activate microglia (Bezzi et al., 2001), and 
can lead to neuronal death (Glass et al., 2010, McCoy and Tansey, 2008).  
 
Impaired neurotransmission has also been associated with microglial activation and 
increased cerebral cytokine synthesis has been reported in animal models of HE 
(Rodrigo et al., 2010). Additionally, Zemtsova et al., (Zemtsova et al., 2011) using in 
vitro and in vivo evidence, as well as postmortem brain tissue, indicated that 
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ammonia directly activates primary rat microglial (induction of activation marker 
proteins, such as Iba-1) and stimulates microglial migration (characteristic of 
activated phenotype). Ammonia also up-regulates the synthesis of reactive oxygen 
species (ROS) proposing the involvement of microglia in inducing oxidative stress, 
but has no effect on glutamate release, induction of inducible nitric oxide synthase 
(iNOS), cyclooxygenase-2 (COX-2; source of proinflammatory prostanoids) and 
synthesis of prostaglandins and proinflammatory cytokines. This study suggests that 
microglia become activated by ammonia but do not reflect the fully reactive microglia 
phenotype. This has also been shown in the cerebral cortex from patients with 
cirrhosis and HE but not in cirrhotic patients without HE, proposing that the reported 
phenotype is a feature of HE but not cirrhosis itself (Zemtsova et al., 2011). 
 
1.1.4 Brain oedema and energy metabolism 
 
One characteristic of HE is brain oedema, defined as the excess accumulation of 
fluid in the intracellular or extracellular space of the brain (Bosoi and Rose, 2013a). 
This can lead to increased ICP, mainly seen in ALF and less frequently in CLD 
patients, which can result in brainstem herniation and death (Jalan et al., 2004a, 
Larsen et al., 1996). Brain oedema can arise either due to cytotoxic, alterations in 
cellular metabolism, or vasogenic mechanisms, which involve the breakdown of the 
BBB. However, instead of a severe oedema observed in ALF, mild cytotoxic or no 
oedema, is seen in CLD (Felipo and Butterworth, 2002b). The variability of results 
reported in these studies regarding brain oedema in CLD is probably due to the 
differences in animal models used (Jayakumar et al., 2013). 
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In ALF unlike CLD, the deficiency of energy metabolism associated with brain 
oedema has been described. This energy dysfunction is believed to be due to a 
compromised tricarboxylic acid cycle enzyme, α-ketoglutarate dehydrogenase 
activity, limited anaplerotic flux and saturated capacity of astrocytes to detoxify 
ammonium by glutamine synthesis, increased lactate synthesis as well as 
mitochondrial permeability transition induced by oxidative stress (Rama Rao and 
Norenberg, 2012, Zwingmann, 2007). At later stages of the disease, several 
mechanisms have been proposed where ammonia detoxification increases 
glutamine concentrations intracellularly, which could secondarily impact energy 
metabolism through an initial osmotic stress, while changes in the glutamate-
glutamine cycle follow.  
 
1.2  Astrocytes  
 
Astrocytes are one of the most numerous glial cells in the brain (Pope, 1978). Until 
recently, their function was thought to be restricted to the provision of structural and 
metabolic support to neurons. However, we are now able to appreciate their 
plasticity and active role in the control of neuronal activity and information processing 
(Navarrete et al., 2012, Sofroniew and Vinters, 2010). Astrocytes are divided in two 
main subtypes, fibrous (white matter) and protoplasmic (grey matter), according to 
their anatomical location and cellular morphology (Ramon Y, 1909). A common 
characteristic of astrocytes is their fine branching processes (Bushong et al., 2002), 
which allows them to make extensive contacts with parenchymal and pial blood 
vessels and therefore be involved in cerebral blood flow (CBF) regulation (Attwell et 
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al., 2010) and control of brain energy metabolism (Sofroniew and Vinters, 2010). 
Furthermore, astrocytes are estimated to contact several hundred dendrites from 
multiple neurons and enwrap about 100,000 synapses (Halassa et al., 2007b, 
Sofroniew and Vinters, 2010, Bushong et al., 2002) a concept known as the 
“tripartite synapse” (pre-post synaptic terminal and glial process) (Araque et al., 
1999, Haydon et al., 2009). This property allows astrocytes to be involved in 
processes such as glial transmission; release of glutamate, ATP/adenosine, D-
Serine and more, as well as neurotransmitter recycling (uptake and enzymatic 
processing) to avoid neurotoxicity at periods of high neuronal activity (Halassa et al., 
2007a, Sofroniew and Vinters, 2010, Henneberger et al., 2010). Furthermore, 
astrocytes are believed to be actively involved in K+ buffering (ion and pH synaptic 
homeostasis) (Kofuji and Newman, 2004, Wallraff et al., 2006) and supply of lactate 
(astrocyte-neuron lactate shuttle) (Magistretti, 2011, Tsacopoulos and Magistretti, 
1996) to neurons when in demand.  
 
Unlike neurons, astrocytes are not electrically excitable. However, they form 
multicellular networks coupled by gap junctions (GJ) and communicate via 
intracellular Ca2+ excitability (Cornell-Bell et al., 1990). These Ca2+ transients can 
pass between astrocytes and across large networks of cells allowing long distance 
communication with other astrocytes. The vast number of receptors and transporters 
that astrocytes express reflects their importance in the brain. These including AQP4, 
K+ and glucose transporters, neurotransmitter transporters for glutamate and GABA, 
that serve to maintain healthy concentrations in the synaptic space, as well as 
purinergic receptors and hemichannels formed by connexins (S. R. McIver, 2013, 
Sofroniew and Vinters, 2010). Moreover, astrocytic end-feet are believed to be 
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contributing to the cellular constituent of BBB (Haussinger et al., 2000, Ballabh et al., 
2004).  
 
There is remarkable heterogeneity in astrocyte population, between different species 
and brain regions in terms of their receptor expression, GJ coupling, membrane 
currents and morphology (Matyash and Kettenmann, 2010). However, the plasticity 
and complexity of these cells during disease, damage or neuronal activity is 
remarkable, which has made them an interesting target for research. Figure 2 
summarises the astrocytic functions in the healthy brain. 
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Figure 2: A schematic summarising the astrocytic function in healthy central nervous 
system. Modified from (Sofroniew and Vinters, 2010) 
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1.2.1 Astrocytes and their role in HE: Is astrocytic “swelling” the main 
problem? 
 
During the course of the disease, once the ammonia disposal capacity of the kidney 
is exceeded, the astrocytes become the major source of detoxification via the 
enzyme GS (Dejong et al., 1993). Furthermore, being an important constituent of the 
BBB, allowing trans-astrocytic transport of substances from the blood to the brain, 
astrocytes could be responsible for alterations in BBB permeability (Haussinger et 
al., 2000). 
 
Interestingly, most of the research in the field has been focused on the anatomical 
alterations of astrocytes, referred to as “swelling”. Is this however the main problem 
when it comes to the development and progression of the disease? 
 
Traditionally, it was believed that astrocytes swell due to the increase in intracellular 
glutamine (more profoundly in ALF), contributing to the neurological phenotype 
observed. Swelling in most cells leads to transport changes designed to cause 
shrinkage of the cells back to the normal levels, a process known as “regulatory 
volume decrease”. These alterations in terms of transport can be due to stretch-
activated ion channels (Kimelberg et al., 1990). Oligodendrocytes, unlike astrocytes, 
were rarely found to swell under pathological conditions in situ, as demonstrated by 
the electrophysiological studies of Kimelberg and colleagues (Kimelberg et al., 
1990). In the same study, it was observed that astrocytic cell-cell coupling decreased 
when the swelling-like phenotype was detected. This can therefore have major 
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effects on the functionality of astrocytes as it can reduce spatial buffering of K+ and 
other substances aimed for removal from the CNS. However, these studies have 
been undertaken in 1990s and a great amount of knowledge has been gained since 
then.  
 
Despite all the critical research being carried out on the astrocytic swelling 
phenotype in the pathogenesis of HE, a recent study by Rangroo Thrane et al., 
(Rangroo Thrane et al., 2013) challenged the hypothesis of astrocyte swelling and 
brain oedema contributing to the onset of ammonia-induced neurological 
dysfunctions. In this study, they examined the direct effect of ammonia on intact 
nervous tissue, avoiding the adaptive changes arising due to chronic exposure (such 
as that seen in CLD), as well as any ammonia-independent pathology accompanying 
liver disease. While current literature suggests that astrocyte swelling underlies 
ammonia neurotoxicity seen in HE, most work done in this area consisted mainly of 
in vitro (cultures-artefact of young age) preparations exposed to high doses of 
ammonia and post-mortem studies in late stages of HE. Rangroo Thrane and 
colleagues using in vivo two-photon imaging observed transient astrocyte shrinkage 
after i.p ammonia injection, lasting from 10 to 30 minutes post infusion. This 
observation contradicts previous hypotheses on astrocytic swelling due to 
hyperammonemia (Hadjihambi et al., 2014b), although time scale at which swelling 
was measured in other studies was not always specified. 
 
Work by Butterworth (Butterworth, 2002) has suggested that reducing ammonia 
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clinical outcomes. However, in awake animals this treatment worsened the 
neurological phenotype by increasing the overall [NH4+]o and [K+]o load on neurons, 
as these were no longer buffered by astrocytes (Rangroo Thrane et al., 2013). 
However, ammonia may not be the only mechanism by which astrocyte swelling is 
triggered in HE. The same phenotype has also been observed in vitro under the 
influence of some neurotransmitters (Bender and Norenberg, 1998, Kimelberg HK, 
1993), benzodiazepines (Bender and Norenberg, 1998, Norenberg, 1998), TNF-α 
(Bender AS, 1992) and hyponatremia (independent predictor of overt HE increasing 
the risk by a factor of eight) (Wakim-Fleming, 2011, Schliess et al., 1996, H. K. 
Kimelberg, 1993). 
 
Finally, the changes seen in astrocytes cannot easily be defined as swelling but 
more as a form of astrogliosis. An example of this, is the Alzheimer type II 
astrocytosis seen in later stages of CLD, which involves large cells with enlarged 
nuclei and cytoplasm, margination of chromatin, mitochondrial and rough 
endoplasmic reticulum (Norenberg, 1977).  
 
1.2.2 Astrocyte-neuron communication 
 
Through the years, the importance of astrocyte-neuronal communication has been 
established. Understanding the role of astrocytes beyond their metabolic and 
structural support to neurons but also in the modulation of neuronal excitation, as 
well as their involvement in the control of breathing (Gourine et al., 2010), memory 
(Henneberger et al., 2010) and other processes has been a breakthrough. In 
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contrast to the well-established alterations of astrocyte morphology, neuronal 
changes have generally been considered to be absent or insufficient to explain the 
neurological features of HE. Histopathologic studies from patients indicate selective 
loss of dopamine D2 receptor density (globus pallidus/putamen), loss of serotonin 
5HT1A sites (cortical/hippocampal), pseudolaminar cortical necrosis and neuronal cell 
loss (basal ganglia, thalamus and cerebellum) (Butterworth, 2007) (Chen et al., 
2014). However, the extent of neuronal cell death in the brains of patients and 
animal models of HE, is considerably less than what would be predicted, suggesting 
the involvement of other cells, such as astrocytes, in protecting the neurons during 
the development of the disease. This underlines the importance of studying the 
astrocyte-neuron communication with the aim of further understanding how 
astrocytic dysfunction contributes to the neuropsychiatric complications arising due 
to the disease.  
 
1.2.3 Astrocyte-neuron lactate shuttle  
 
Brain information processing requires constant and sufficient supply of oxygen and 
metabolic substrates. Astrocytes store glycogen (the only cells that have this feature) 
and represent an important source of lactate, which contributes to the extracellular 
pool of readily available metabolic substrates taken up by neurons to fuel their 
activity (Pellerin and Magistretti, 1994, Cataldo and Broadwell, 1986). As suggested 
by the astrocyte-neuron lactate shuttle, lactate produced by astrocytes is released 
into the extracellular space where it’s taken up by neurons (Pellerin and Magistretti, 
1994, Pellerin and Magistretti, 2012). This mechanism is believed to exist for the 
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supply of lactate as one (even primary) fuel to meet metabolic demands of active 
neurons (Patet et al., 2015). Furthermore, in vivo studies exist proposing the idea 
that lactate release reduces the glutamate induced neurotoxicity and exerts a 
neuroprotective effect (Ros et al., 2001). While previously, lactate transport across 
the cell membranes was thought to be achieved solely via operation of 
monocarboxylate transporters (MCTs), a recent study (Karagiannis et al., 2016) 
demonstrated the role of connexin hemichannels (discussed in more detail in section 
1.3) as equally important conduits of lactate transport across the membrane.  
 
1.2.4 Brain lactate and liver disease 
 
Recent data has indicated that physiological levels of ammonia applied to astrocytes 
in mixed cortical cultures and in the somatosensory cortex of anesthetised rats, 
cause an acute rise in cytosolic lactate followed by its release (Lerchundi et al., 
2015). This is believed to be due to mitochondrial matrix acidification resulting in a 
strong inhibition of mitochondrial pyruvate uptake and consequently lactate 
production and release. Increased brain lactate synthesis has been reported in 
hyperammonemic conditions such as ALF (Rose, 2010), due to the inhibition of the 
tricarboxylic acid cycle enzyme α-ketoglutarate dehydrogenase, reflecting a 
reduction in oxidative metabolism and impaired energy metabolism (Rose et al., 
2007, Lai and Cooper, 1986).  
 
In animal models of ALF and ALF patients, an increase in brain lactate has 
consistently been reported. 
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cirrhotic and CLD patients but only in severe cases of HE (>grade 2) (Yao et al., 
1987). Additionally, the study by Bosoi et al., (Bosoi et al., 2014) revealed for the first 
time in the setting of CLD that increased cerebral lactate (recorded using NMR 
spectroscopy) is associated to the pathogenesis of brain oedema (cytotoxic). 
Furthermore, an ex vivo study in 6 weeks bile duct ligated (BDL) rats (a clinically 
relevant model of CLD) showed that a rise in lactate (1.7 fold), and not glutamine, 
played an important role in the pathogenesis of brain oedema (Bosoi et al., 2014). In 
contrast, Rackayoya et al. (Rackayova et al., 2016) reported no significant elevation 
of lactate in rats 8 weeks following BDL, which is a very severe model of HE. These 
observations are contradictory and the variability may be explained by the different 
techniques used in each study. Since it is believed that brain oedema in liver disease 
is mainly cytotoxic, these results imply that the observed increase in total brain 
lactate is due to its intracellular accumulation.  
 
Despite the existing evidence, it remains unknown whether significant changes in 
brain lactate metabolism develop in conditions of long-term CNS exposure to 
increased ammonia concentrations, such as that seen during CLD or HE.  
 
1.2.5 Brain glutamate and liver disease 
 
A glutamate-glutamine metabolic cycle exists between astrocytes and neurons and 
its role is to metabolize the glutamate that has been released from neurons, 
preventing over excitation (Cooper, 2001). Glutamate released by presynaptic 
neurons induces signalling through glutamate receptors. The excess is then cleared 
up by astrocytic excitatory amino acid transporters (EAAT), converting it to glutamine 
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by GS and preventing glutamate accumulation (Bosoi and Rose, 2013a, Kimelberg, 
2005). An increase in extracellular glutamate has previously been documented in 
rats with portocaval anastomosis, associated with severe HE (Oria et al., 2012), 
while extracellular glutamate recorded using microdialysis, in rats with ALF, 
increases as a function of the deterioration of neurological status (Michalak et al., 
1996). This increase in extracellular glutamate concentrations has been described to 
occur as a result of decreased mRNA and protein expression of astrocytic glutamate 
transporters (Suarez et al., 2000). Additionally, human studies have also shown 
increased glutamate in the CSF of patients with liver cirrhosis and HE (Weiss et al., 
2016, Watanabe et al., 1984). In CLD, decreased uptake of glutamate, rather than 
altered transporter expression, has been reported in various preparations (Schmidt 
et al., 1990), while several studies have discussed the potential role of other factors 
such as oxidative stress (Blanc et al., 1998b) or manganese (Rose et al., 1999) in 
interfering with glutamate transport even in the absence of changes in transporter 
expression (Vaquero and Butterworth, 2006). 
 
Added to the alterations in glutamate uptake, studies in cultured astrocytes suggest 
that acute ammonia application leads to increased glutamate release involving a pH-
mediated, Ca2+-dependent mechanism (Rose, 2002, Rose et al., 2005). Further 
studies proposed that astrocyte swelling is associated with prostanoid-dependent 
glutamate exocytosis, which triggers an oxidative/nitrosative stress response by way 
of N-methyl-D-aspartate (NMDA) receptors (Gorg et al., 2010), and induces tyrosine 
nitration on key astrocytic proteins, as well as RNA oxidations (in neurons and 
astrocytes) (Gorg et al., 2008, Schliess et al., 2002). This can result in alterations on 
local postsynaptic protein synthesis and gene transcription. Furthermore, densities of 
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the high affinity glutamate receptor, NMDA has been reported to show significant 
reduction in cerebral cortex, hippocampus and basal ganglia structures of 
portacaval-shunted rats (Peterson et al., 1990), while a decrease in the activity of 
NMDA receptor-induced production of cyclic guanosine monophosphate has also 
been observed (Erceg et al., 2005). 
 
Adding to the reported changes in the glutamate-mediated neurotransmission, as 
previously discussed by Albrecht et al., (Albrecht and Jones, 1999) in HE associated 
with CLD, there is an imbalance between excitatory and inhibitory 
neurotransmission. As suggested by Rangroo Thrane et al., (Rangroo Thrane et al., 
2013) compromises of the inhibitory neurotransmitter, gamma-aminobutyric acid 
(GABA), arising due to elevated ammonia concentrations, could be partly 
responsible for the altered levels of consciousness occurring in HE. Finally, ammonia 
also affects other neurotransmitter systems including the synthesis of histamine, 
serotonin, dopamine and noradrenaline in the brain (Oja et al., 2017). 
 
1.2.6 Astrocyte: functional oxygen sensors and their role in neurovascular 
coupling 
 
Oxygen is essential for all complex forms of life and the brain is highly vulnerable to 
oxygen deprivation. The existence of a functional CNS oxygen sensor has been 
supported by several studies, with evidence showing that the brainstem, the 
respiratory and cardiovascular control circuits, are sensitive to oxygen changes (Sun 
and Reis, 1994, Marina et al., 2015). The cellular identity and molecular mechanism 
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of these sensors was unknown, until a recent study by Angelova et al., (Angelova et 
al., 2015) identified astrocytes as functional oxygen sensors.  
 
As previously discussed, the anatomical location of astrocytes places them at a 
strategic advantage to detect both synaptic activity and changes in vascular partial 
pressure of oxygen (PO2). Remarkably, PO2 threshold of astroglial activation is lower 
than that of the carotid body glomus cells (peripheral chemoreceptors), residing 
approximately 10 mmHg below normal brain oxygen levels of approximately 25 
mmHg (Marina et al., 2015, Zhang et al., 2015). This activation of astrocytes occurs 
in the absence of peripheral oxygen sensing, suggesting that their role involves both 
contributing and preserving significant components of the homeostatic respiratory 
response during hypoxia (however this remains highly controversial, for a recent 
review see (Gourine and Funk, 2017)). The proposed sensory mechanism of these 
cells (shown in cultured cells, brain slices and in vivo) involves mitochondrial 
depolarisation. This, in combination with the increased rate in ROS production and 
lipid peroxidation leads to an activation of phospholipace C, inositol triphosphate 
(IP3) receptor and recruitment of Ca2+ from internal stores. Finally, the rise in [Ca2+]i  
results in vesicular ATP release (Gourine et al., 2005). Detection of low PO2 by 
brainstem astrocytes stimulate networks of respiratory neurons and contribute to the 
overall respiratory response to hypoxia, ensuring appropriate oxygenation of arterial 
blood. Other mechanisms, such as ryanodine receptor activation by ROS cannot be 
excluded (Green et al., 2002).  
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The neurovascular unit is a conceptual model encompassing the anatomical and 
metabolic interactions between neurons, vascular components [endothelial cells, 
pericytes, vascular smooth muscle cells (VSMC)] and glial cells (astrocytes, 
microglia) in the brain (Venkat et al., 2016). In order to sustain neuronal function, the 
“neurovascular coupling” mechanism has evolved in the brain, resulting in 
hemodynamic responses, which induce vasodilation and increase CBF to the 
regions of active neurons (known as functional hyperaemia). While a significant 
controversy exists in literature regarding the cells mediating this effect, available in 
vitro and in vivo evidence indicate astrocytes (and pericytes) as essential 
contributors in vasomotor responses, participating in both vasodilation and 
vasoconstriction (Attwell et al., 2010, Belanger et al., 2011). Ca2+ transients in 
astrocytes resulting in metabotropic glutamate receptor activation, activates cytosolic 
phospholipase A2, triggering the formation of arachidonic acid, which is then 
converted into vasodilating agents such as prostaglandin E2 (PGE2) (Attwell et al., 
2010, Belanger et al., 2011). Alternatively, arachidonic acid can diffuse in VSMC and 
cause vasoconstriction after its conversion in 20-Hydroxyeicosatetraenoic acid 
(Belanger et al., 2011). Interestingly, studies exist indicating that vasodilation and 
vasoconstriction may be dictated by the release of metabolic substances, such as 
lactate, which depend on the metabolic state of the brain (Gordon et al., 2008). It is 
suggested that under conditions of low oxygen, astrocytic Ca2+ concentration is 
elevated and extracellular lactate and adenosine increases. High external lactate 
hinders PGE2 clearance and increases extracellular PGE2, which causes an 
astrocytic-mediated vasodilation.  
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While the neurovascular unit and therefore the cerebral perfusion and oxygenation 
are controlled by various mechanisms, it can be compromised under pathological 
conditions (Ostergaard et al., 2014). In patients with cirrhosis and HE, cerebral 
metabolic rate of oxygen (CMRO2) and CBF are believed to be reduced, compared 
to patients with cirrhosis without HE and in healthy individuals (Dam et al., 2013), 
while post-mortem examinations revealed altered vasculature in severely affected 
brains, such as proliferation of capillaries (probably due to increased vascular 
resistance) (Butterworth, 2007). Additionally, several studies indicated a preserved 
cerebral autoregulation (the ability to maintain a constant blood flow despite changes 
in perfusion pressure) in most patients with cirrhosis (~77%) but it is impaired in 
severe cases of HE (Strauss et al., 2000). However, the degree of brain hypoxia and 
the mechanisms underlying any alterations occurring in HE remain unknown.  
 
1.3  Connexin Hemichannels 
 
As previously discussed, astrocytes are extensively coupled by GJ, allowing a direct 
passage of molecules between cells. GJ channels spin two plasma membranes and 
consist of two hemichannels (connexons), one from each cell. Each hemichannel is 
formed by six connexin subunits (Figure 3A-C), and is permeable to small molecules 
up to 1-1.5kD (Sohl and Willecke, 2004). Their role involves electrical conductance 
(essential in neurons) and metabolic assistance, transferring ions, glucose, ATP, 
amino acids, signalling molecules (Giaume et al., 2010, Giaume et al., 2013). 
Astrocytic GJ communication is believed to be modulated by cytokines, growth 
factors, neurotransmitters, NO and other factors, making them a subject to change 
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under certain conditions, such as neuronal injury (Rouach et al., 2000, Blanc et al., 
1998a).  
 
Connexins consist of 4 transmembrane helices (M1-M4) (Figure 3A). The N- and C- 
terminal ends are intracellular. The primary sequence of the intracellular loop is not 
well conserved, while the C-terminal sequence varies a lot between connexins with 
connexin-26 being ~20 amino acids and connexin-43 being 150 amino acids long 
(Fiori et al., 2014). A number of connexins have been identified, with their expression 
pattern varying between cell types, brain regions and developmental stage. Neurons 
express connexin-26, connexin-30, connexin-36, connexin-45 and connexin-47 
(Rouach et al., 2002), while astrocytes predominantly express connexin-43, 
connexin-26, connexin-30, connexin-40, connexin-45 and connexin-46 (Giaume et 
al., 2012), with connexin-43 and connexin-30 being the most abundant astrocytic 
connexins (Giaume et al., 2010). Across connexin isoforms, there is a variation in 
unitary conductance (most hemichannels have a fixed negative charge in the pore 
therefore cation selective) and permeability characteristics that have likely evolved 
according to the requirements of the tissue in which they are expressed. Moreover, 
their plasticity allows them to compensate for the loss or down regulation of other 
connexins as revealed by several KO models (Sohl and Willecke, 2004).  
 
Connexins can also exist as functional hemichannels allowing the exchange of ions 
and signalling molecules between the intra and the extracellular milieu (Giaume et 
al., 2010, Rouach et al., 2000) (Figure 3B). Under normal physiological conditions, 
hemichannels are either closed (Contreras et al., 2003) or in a flickering state (Figure 
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3D) (Bukauskas and Peracchia, 1997). Maintaining a controlled gating is very 
important to preserve a normal cell function. Hemichannels are therefore constantly 
under the control of several factors such as membrane potential, pH, 
posttranslational modification (phosphorylation, ubiquitination, S-nitrosylation), 
mechanical stimulations and intracellular/extracellular [Ca2+] (Giaume et al., 2013, 
Retamal, 2014). A summary of the conditions, which trigger opening and closing of 
hemichannels is listed in Table 1. In certain pathological conditions, such as epilepsy 
and ischemia, significant changes in astrocyte structure and function may occur, 
which are associated with changes in hemichannel activity, affecting coupling within 
the astroglial networks and their communication with other brain cells (Giaume et al., 
2010). Facilitated opening of hemichannels has been shown to correlate with cell 
death by loss of osmoregulation, excitotoxicity and spread of inflammation (Kim et 
al., 2017). While the exact gating mechanism of hemichannels is still unclear, the ball 
and chain mechanism is proposed to explain the closure of connexin-43 
hemichannels in response to intracellular acidification. The C-terminal domain acts 
as a ball that interacts with the intracellular cytoplasmic loop occluding the pore (Fiori 
et al., 2014). Finally, the N-terminal region is believed to act in a similar way for 
voltage gating of hemichannels, while calmodulin domains on the C-terminal allow 
gating of the hemichannels by changes in [Ca2+] (Fiori et al., 2014).  
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Open conformation  Close conformation  
<1.4 mM [Ca2+]o Negative membrane potential 
Increase ROS Low pH 
Mechanical stress Phosphorylation (predominantly 
Ser368) 
TNF- α, IFN- γ and IL-1β IL-6 
Ischemia and hypoxia High [Mg2+] 
Hypercapnia (Connexin-26 act as 
CO2 sensors) 
Lanthanum, Cobalt and Nickel 
Quinine/quinide Gadolinium, Carbenoxolone and 
NPPB 
NO (through N-nitrosylation) Chronic hyperammonemia? 
 
Table 1: Conditions/factors, which facilitate opening and closing of connexin 
hemichannels. In red bold writing is one of the hypotheses, which is addressed in this 
study. Information was gathered from (Giaume et al., 2013, Retamal, 2014) (Fiori et al., 
2014, de Wolf et al., 2017, Saez et al., 2013, Trexler et al., 1999, Willebrords et al., 2016, 
Batra et al., 2012). ROS: reactive oxygen species, NO: nitric oxide, TNF- α: Tumor necrosis 
factor alpha, IFN- γ: Interferon gamma, IL-1β: Interleukin 1 beta, NO: nitric oxide, NPPB: 5-
Nitro-2-(3-phenylpropylamino)benzoic acid. 
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Figure 3: Connexin, hemichannel and gap junction channel representation. A. 
Schematic illustrating the 4 transmembrane domains (M1-M4) of a connexin channel. The 
intracellular sequences (N-terminal region, intracellular (IC) loop and the C-terminal domain) 
are involved in channel gating. B. Schematic drawing of a connexin hemichannel made of 
six connexins. C. Schematic indicating the formation of gap junction channels, consisting of 
two hemichannels, one from each cell. D. Schematic of hemichannel gating configuration at 
baseline conditions, at exposure to stimuli such as hypoxia and/or 0 [Ca2+]o as well as in the 
presence of connexin hemichannel blockers such as 5-Nitro-2-(3-
phenylpropylamino)benzoic acid (NPPB) and Carbenoxolone (CBX). Modified from (Bao et 
al., 2005, Fiori et al., 2014) 
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1.4  The glymphatic system: waste clearance pathway of the brain 
 
As discussed above, there is evidence that many potentially noxious substances and 
metabolites such as lactate, glutamate, neurosteroids, bile acids and various drugs 
accumulate in the cerebral interstitial fluid (ISF) and cerebrospinal fluid (CSF) of HE 
patients (Weiss et al., 2016). It is however still unclear why this build-up of toxins 
occurs.  
 
In the peripheral tissues, the lymphatic system accounts for clearance of ISF and 
solutes, a critical process, which ensures tissue homeostasis. Despite the brain 
being characterized by a high metabolic rate and the exquisite sensitivity of neurons 
and glia to alterations in the extracellular environment, the brain was believed to be 
devoid of a lymphatic drainage system. However, recent studies have identified a 
brain-wide paravascular clearance pathway that facilitates the efficient removal of 
interstitial proteins, peptides and other molecules from the brain (Iliff et al., 2013a, 
Iliff et al., 2012). These studies showed that subarachnoid CSF recirculates through 
the brain parenchyma along paravascular spaces surrounding penetrating arteries, 
exchanging with the surrounding ISF to facilitate the clearance of interstitial solutes 
via convective bulk flow. Paravascular CSF-ISF exchange and solute clearance is 
dependent upon water transport via astrocytic AQP4 channels, which are localized 
predominantly on perivascular astrocytic end-feet. ISF and its constituents in turn are 
cleared along paravascular spaces surrounding large calibre cerebral veins, which 
then reach the recently discovered CNS lymphatic vessels (Louveau et al., 2015) 
and eventually enter systemic circulation. This pathway has been termed the 
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“glymphatic system” due to its dependence on glial water channels, summarized in 
Figure 4 and its adoption of a clearance function similar to peripheral lymphatic 
system.  
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Figure 4: Brain glymphatic system. The perivascular drainage pathway moves waste into 
the periarterial space and towards the subarachnoid space in the direction opposite to blood 
flow. The water component of cerebrospinal fluid (CSF) crosses astrocytic aquaporin 4 
(AQP4) channels to enter the brain parenchyma. CSF - interstitial fluid (ISF) exchange takes 
place within the brain parenchyma via convective flow. CSF - ISF then moves into the 
perivenous space of deep-draining veins. Effluxed waste can then recirculate with the CSF, 
or be absorbed into the newly discovered CNS lymphatic vessels (Louveau et al., 2015) and 
eventually enter systemic circulation. Arrows indicate direction of flow. Modified from 
(Nedergaard, 2013). 
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The glymphatic system plays an essential role in ensuring healthy function of the 
brain. In addition to clearing the brain, it may also contribute to the distribution of 
growth factors, neuromodulators, and other solutes, while failure of the glymphatic 
system may have important pathophysiological consequences, such as those seen 
in the aging brain (Kress et al., 2014) and Alzheimer’s disease (Iliff et al., 2012, Peng 
et al., 2016).  
 
It is well known that sleep improves memory and helps regulate the metabolism of 
the body (intrinsically connected to hormonal regulation such as growth hormone, 
leptin, ghrelin and more), while prolonged sleep deprivation impairs cognitive 
performance, elevates stress and is a common cause of seizures. A recent study 
has proposed that during sleep, glymphatic activity is dramatically enhanced while its 
function is suppressed during wakefulness. It has been suggested that a key function 
of sleep is to support the activity of the glymphatic system and clearance of 
potentially neurotoxic waste substances produced during wakefulness (Xie et al., 
2013). Interestingly, CLD and HE are always accompanied by dyssomnia (Bajaj et 
al., 2011). mHE patients suffer from poor sleep quality, take longer time to fall 
asleep, exhibit lower sleep efficiency and slow daytime functional disturbances (Liu 
et al., 2015). Aside from anxiety and depression, other psychiatric factors tend to 
have a negative impact on sleep quality, which results in a vicious cycle and further 
health deterioration. The efficacy of the glymphatic system has not been investigated 
yet in the context of HE and studies of this type might be able to provide invaluable 
information regarding the diagnosis and treatment of HE patients.  
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1.5  Main Hypothesis and Aims 
 
Experimental studies described in this thesis tested the hypothesis that during the 
development of HE, chronic exposure to elevated ammonia concentrations alters 
cerebral oxygenation, compromises lactate transport between astrocytes and 
neurons and affects uptake of neurotransmitters. It was also hypothesised that HE 
impairs glymphatic clearance mechanisms, either as a cause or a consequence of 
the disease, which contributes to the cognitive impairment.  
 
In vivo whole animal (rat) and in vitro experimental models were used to address the 
following specific aims:  
1. To determine whether cerebral oxygenation is impaired in HE and, if so, 
explore the potential underlying mechanisms (Chapter 2); 
2. To determine whether in HE, the actions of high ammonia alter brain 
extracellular lactate concentration and, if so, study the potential underlying 
mechanisms (Chapter 3); 
3. To determine whether in HE the actions of high ammonia alter brain 
extracellular glutamate concentration (Chapter 4); 
4. To evaluate the efficacy of brain glymphatic clearance pathway in HE and 
determine the potential cognitive/behavioural consequences of impaired 
glymphatic flow (Chapter 5).  
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Chapter 2: Ammonia triggers impaired cerebral oxygenation in 
an animal model of chronic liver disease with minimal hepatic 
encephalopathy. 
 
2.0  Introduction 
 
Despite only ~2% of total body weight, the brain receives ~15% of cardiac output 
and is responsible for 20% of the body’s total oxygen and glucose consumption 
(Kisler et al., 2017, Attwell et al., 2010). Mechanisms within the brain have evolved to 
control blood flow to active areas in order to match metabolic supply and demand, 
known as neurovascular coupling (Attwell et al., 2010). Due to the limited energy 
reserve in the brain, if CBF is interrupted then neuronal functionality ceases within 
seconds (Moskowitz et al., 2010). Long-term impairment of this mechanism has 
been linked to the development and/or progression of the cognitive impairment in 
aging and Alzheimer’s disease (Lourenco et al., 2015). Additionally, acute 
impairment can have long-term consequences on neurological function (Khot and 
Tirschwell, 2006). Clearly, maintaining appropriate CBF is essential for supporting 
neuronal function and therefore, cognition.  
 
The precise mechanisms controlling neurovascular coupling have not yet been fully 
elucidated however, studies have shown that a group of cells known as the 
neurovascular unit (neurons, astrocytes, and endothelial cells) function in concert to 
ensure blood supply is delivered to active areas. Astrocytes, and pericytes at the 
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capillary level, are also thought to mediate communication between neurons and 
blood vessels (Attwell et al., 2010, Iadecola, 2004, Hall et al., 2014, Mishra et al., 
2016).  
 
In patients with liver cirrhosis and HE, CMRO2 and CBF are believed to decrease, 
compared to patients with cirrhosis without HE and healthy controls (Dam et al., 
2013). Additionally, several studies indicate a preserved cerebral autoregulation in 
most patients with cirrhosis (~77%), which is impaired in more severe cases of HE 
(Strauss et al., 2000). Results from functional magnetic resonance studies also 
revealed that patients with HE have abnormal activation in several brain regions 
when performing selected cognitive tasks, proposing a possibly uncoupled 
neurovascular unit (Zhang et al., 2007). These changes may bring the brain into a 
general dysmetabolic state. In such state of low activity and low oxygen 
consumption, mechanisms are likely to be triggered resulting in decreased oxygen 
delivery (less demand less supply) and therefore further brain atrophy. However, the 
precise level of brain tissue oxygenation and the mechanisms behind any alterations 
occurring due to the disease, are still unknown. 
 
Studies showing impaired CMRO2 and CBF did not observe a correlation with 
arterial ammonia concentration or cerebral metabolic rate of ammonia (Iversen et al., 
2009). The results of these studies do not support a direct effect of 
hyperammonemia on brain oxidative metabolism but do not preclude other or indirect 
roles of ammonia.   
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This study determined whether cerebral tissue oxygen tension and CO2 
cerebrovascular reactivity are altered in animal models of HE. Ornithine 
phenylacetate (OP, OCR-002; Ocera Therapeutics, CA, USA) has been shown to 
reduce ammonia concentration (in plasma and brain) in animal models of cirrhosis 
and ALF (Jalan et al., 2007). OP treatment was found to be associated with a 
significant reduction in the severity of brain swelling (Jalan et al., 2007), 
improvement in neurophysiological function (Oria et al., 2012) and reduction in 
intracranial pressure (Ytrebo et al., 2009). Therefore, OP was applied in this study as 
an experimental ammonia-lowering treatment. The data obtained demonstrate that, 
in HE, ammonia actions contribute to the compromised cerebral oxygenation but 
have no effect on cerebrovascular reactivity to CO2. The cause of the low basal brain 
tissue PO2 remains unknown however; compromised cerebral perfusion could be a 
contributing factor.     
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2.1  Materials and Methods 
 
All the experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 (ASPA) revised according to the European Directive 
2010/63/EU and the UK Home Office (Scientific Procedures) Act (1986) with project 
approval from the Institutional Animal Care and Use Committee.  
 
2.1.1 Animal models  
 
Male Sprague-Dawley rats (body weight ~350-400g) were obtained from a 
commercial supplier (Charles Rivers Laboratories, Inc.). 
 
BDL surgery: Under general anaesthesia (5% isoflurane in oxygen for induction, 2% 
isoflurane in air for maintenance) 24 rats underwent triple ligation of the bile duct via 
a small laparotomy to induce chronic liver injury and were studied 28 days after the 
surgery (Harry et al., 1999). 
 
Sham surgery: Under general anaesthesia (5% isoflurane in oxygen for induction, 
2% isoflurane in air for maintenance) 21 rats underwent sham surgery. Via a small 
laparotomy, the bile duct was detected and exposed for several seconds, prior 
closure of the incision. Sham-operated animals were studied 28 days after the 
surgery. 
	 38	
OP treatment: 3 weeks after the surgery, 6 BDL and 7 Sham-operated rats were 
given twice daily intraperitoneal injections of combined L-ornithine and phenylacetate 
(0.3g/kg; OP) ~7 hours apart for 5 days – a dosing regimen that has previously been 
shown to effectively reduce plasma ammonia concentration (Davies et al., 2009). 
The rats were studied on day 28 post BDL surgery, within 3 hours of the last OP 
injection. 
 
Blood and brain tissue were collected under terminal isoflurane anaesthesia. Plasma 
biochemistry was performed using a Cobas Integra II system (Roche Diagnostics). 
 
2.1.2 Measurement of brain tissue PO2  
 
Sham (n=14), BDL (n=18), Sham-OP treated (n=7) and BDL-OP treated (n=6) rats 
were anesthetized with α-chloralose (100mg kg-1), instrumented for arterial blood 
pressure recording and artificially ventilated. Arterial blood samples were collected at 
regular intervals and analysed using a pH/blood gas analyser (Siemens Rapidlab 
248; Siemens Healthcare, Sudbury, UK). Arterial PO2 was maintained within the 
physiological range by adjusting the rate and/or stroke volume of the ventilator. 
Cerebral tissue PO2 was monitored by optical fluorescence (Oxylite™, Oxford 
Optronics). The sensor is based on optical fluorescence technology that allows real-
time detection of PO2. After a limited craniotomy, oxygen sensors were placed in the 
somatosensory cortex (0.5–1 mm below the cortical surface) and sealed from the air. 
Tissue PO2 was recorded at baseline and during systemic hypercapnia (10% CO2; 5 
min). 
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2.1.3 Pharmacological interventions  
 
It has been previously reported that systemic arterial blood pressure is lower in 
conscious BDL animals at 4 weeks post ligation (Estrela et al., 2016). It was also 
noted that under anaesthesia, BDL animals have a significantly lower mean arterial 
pressure (MAP) than Sham controls. In order to control for the effects of lower 
perfusion pressure, an alpha1-adrenoceptor agonist, phenylephrine (PE) was used 
to increase systemic blood pressure in the BDL animals equal to that of Sham 
controls. PE was infused at a rate of 5-10µg min-1 to maintain a MAP of ~100 mmHg 
for a period of approximately 10mins. 
 
In order to investigate the role of cerebral perfusion in brain oxygenation during liver 
disease, the carbonic anhydrase inhibitor acetazolamide (ACTZ) was used. ACTZ 
increases CBF (Vorstrup et al., 1984) (by decreasing pH-protons cause smooth 
muscle relaxation) and cerebral oxygenation, which confer some of its therapeutic 
benefits (Wang et al., 2015). It is also used prophylactically to prevent acute altitude 
sickness. Sham-operated and BDL animals received 10mg kg1 (i.v.) ACTZ (in 100% 
DMSO) after a baseline PO2 was recorded.   
 
2.1.4 Statistical analysis 
 
For the analysis of differences in blood PO2/PCO2 and brain PO2 between animal 
groups, Kruskal-Wallis test followed by Dunn’s multiple comparison post-hoc test 
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was applied. The analysis of pharmacological interventions and CO2 reactivity was 
performed using one-way ANOVA for comparison between the animal groups 
(comparing changes of PO2 due to drug/CO2 application) and paired sample t-test for 
comparison within groups (evaluating the effect of drug/CO2 before and after 
application). 
 
The biochemistry data was analysed using one-way ANOVA. Data are reported as 
mean±SEM. Differences with p value of <0.05 were considered to be significant. 
Statistical analysis was performed using OriginPro 9.1 (OriginLab).  
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2.2  Results 
2.2.1 Biochemistry 
 
Plasma biochemistry, including ammonia concentration was assessed in all groups 
of animals (Table 2). Compared to Sham surgery, BDL resulted in a significant 
increase in plasma ALT and bilirubin (p<0.001), indicating impaired liver function, 
while albumin and total protein concentrations were significantly decreased 
(p<0.001). Treatment of BDL rats with OP had no effect on these parameters (Table 
2). Plasma ammonia concentration was significantly higher in BDL rats when 
compared to Sham-operated animals (p<0.001). Treatment of BDL animals with OP 
lowered plasma ammonia concentration, which was similar to that measured in 
Sham-operated animals (p=0.3) (Table 2). 
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Parameters Sham BDL BDL+OP Sham+OP 
N numbers 22 60 30 7 
Ammonia, µmol/L 56±3 141±1** 61±0.5 50±5 
Albumin, g/L 35±4 23±0.2** 23±1 30±2 
Total protein, g/L 50±0.3 38±0.3** 42±0.5 53±1 
Bilirubin, µmol/L 5±0.5 205±1** 163±2 6±0.5 
ALT, U/L 11±0.4 130±0.5** 86±1 13±0.5 
 
Table 2: Plasma biochemistry. ALT: alanine aminotransferase. Data expressed as 
means±SEM, ** p<0.001 compared to Sham group using one-way ANOVA. 
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2.2.2 Brain tissue PO2 and cerebrovascular CO2 reactivity in animal models of 
HE 
 
Following placement of the oxygen sensor in the cerebral cortex, blood PO2 and 
PCO2 were maintained constant at ~121±2 mmHg and 32±1 mmHg, respectively, in 
Sham-operated animals (n=14) and 114±3 mmHg, (PO2, p=0.2) and 33±1 mmHg 
(PCO2, p=1), respectively, in BDL animals (n=18), ensuring equal arterial 
oxygenation (Figure 5A-B). 
 
Once blood gases were stabilized, cerebral PO2 was obtained at several time points 
revealing a significantly lower brain PO2 of 13±2 mmHg (p<0.001) in BDL animals 
compared to Sham-operated controls (26±1 mmHg) (Figure 6). 
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Figure 5: Brain PO2 and PCO2 in an animal model of HE. A. Blood PO2 and B. PCO2 are 
not significantly different between the animal models. 
 
 
Figure 6: Brain PO2 in an animal model of HE. Basal PO2 in the somatosensory cortex is 
lower in BDL animals but recovers with the ammonia lowering treatment (OP). 
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In order to evaluate the ability of vessels to respond to a known vasodilatory 
stimulus, systemic hypercapnia (10% CO2) was applied. Despite the lower PO2 
baseline, CO2 reactivity was preserved in BDL animals (n=6), with an increase in 
PO2 (by 21±2 mmHg, p=0.6) similar to the one recorded in Sham-operated animals 
(by 24±2 mmHg, n=8) (Figure 7). 
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Figure 7: Cerebrovascular reactivity to hypercapnia (10% inspired CO2) is unchanged 
in BDL animals when compared to Sham-operated controls, despite lower basal PO2. 
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2.2.3 Normalisation of MAP does not restore brain tissue PO2 but increasing 
CBF potentially does  
 
While data exists in patients indicating preserved autoregulation, the possibility of 
low MAP recorded in BDL animals (57±3 mmHg) contributing to the compromised 
cerebral PO2, was attempted to be excluded. PE, an α1-adrenergic receptor agonist, 
was infused i.v, increasing MAP in BDL animals to ~100-120 mmHg, which is the 
normal blood pressure recorded in healthy control rats under anesthesia (Figure 8). 
Both animal groups showed a significant increase in brain tissue PO2 from the 
corresponding baseline (Figure 8-9), although the overall change in oxygen was 
significantly lower in the BDL (by 6±1 mmHg, n=6, p=0.02) compared to Sham-
operated animals (by 18±6 mmHg, n=6) (Figure 10A). The PO2 of BDL animals 
treated with PE was also significantly lower than the PO2 baseline of Sham-operated 
animals (p=0.02) suggesting that the intervention did not restore cerebral PO2 of 
BDL animals back to normal values. 
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Figure 8: Representative traces from BDL animals indicating cerebral PO2 and blood 
pressure before, during and after i.v infusion of PE and ACTZ. 
  
 
 
 
Figure 9: Representative traces from Sham-operated animals indicating cerebral PO2 
and blood pressure before, during and after i.v infusion of PE and ACTZ. 
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Figure 10:  Brain PO2 is not restored in the BDL animals when MAP is normalised but 
it improves when CBF is increased. A. Summary and individual data illustrating the effect 
of PE infusion, increasing MAP, on the cortical PO2 of Sham-operated and BDL rats. B. 
Summary and individual data illustrating the effect of ACTZ infusion, increasing CBF, on the 
cortical PO2 of Sham-operated and BDL rats. The dotted line indicates normal brain PO2 
values. 
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ACTZ, a carbonic anhydrase inhibitor, induces an increase in both CBF and blood 
volume in the normal brain. According to literature, CBF in patients with HE is 
compromised. Following a protocol from a previous MRI study performed in Prof. 
Gourine’s laboratory, a concentration of ACTZ known to increase CBF successfully 
(by 85 ml/100g/min which corresponds to an increase of 102% from baseline CBF) 
was infused and changes in brain PO2 were recorded. A significant increase in 
oxygen from the corresponding baseline was observed in both animal groups with 
the overall change in oxygen not being significantly different between BDL (5±2 
mmHg, n=6, p=0.05) and Sham-operated animals (11±2 mmHg) (Figure 8-9, 10B). 
ACTZ treatment was potentially effective in normalising the cerebral PO2 of BDL 
animals (after treatment), which was not significantly different from the Sham-
operated baseline PO2 before treatment (p=0.08) (Figure 10B). 
 
2.2.4 Ammonia lowering treatment prevents fall of brain tissue PO2  
 
Daily OP treatments had been shown to decrease systemic and brain ammonia 
concentrations in BDL animals (Davies et al., 2009). In the experiments described in 
this thesis, OP treatment of BDL rats significantly improved cerebral PO2 (22±1 
mmHg, n=6, p=1), increasing the oxygen tension to levels similar to that recorded in 
Sham-OP rats (27±2 mmHg, n=7), when blood PO2 and PCO2 were constant (Sham-
OP: PO2: 116±2 mmHg, PCO2: 34±2 mmHg; BDL-OP: PO2: 115±5 mmHg, p=1; 
PCO2: 31±2 mmHg, p=1) (Figure 5-6). 
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2.3  Discussion 
 
Brain information processing requires constant and sufficient supply of oxygen and 
metabolic substrates. Compromised tissue oxygenation can have detrimental effects 
on all cell types, with the development of severe clinical symptoms in the long term. 
Several studies have reported compromised CBF and CMRO2 due to HE (rather 
than cirrhosis) (Dam et al., 2013), with no clear mechanistic insights and 
contradictory data regarding the role of ammonia.  
 
Several mechanisms exist in the brain ensuring adequate cerebral perfusion such as 
cerebral autoregulation, which seeks to maintain constant CBF. In this study, 
cerebral tissue PO2 was monitored directly, for the first time, using optical 
fluorescence, in animal models of CLD with mHE. At a constant blood PO2 and 
PCO2, a significantly lower brain tissue PO2 was recorded in BDL animals compared 
to Sham-operated rats. While evidence of preserved autoregulation exists in patients 
with HE, restoring MAP did not normalise cerebral PO2 in BDL animals, suggesting 
that the decreased brain oxygenation is not due to relative hypotension. However, 
increasing CBF acutely using a pharmacological intervention like ACTZ, improved 
brain tissue PO2.  
 
While these interventions may provide some information regarding the mechanisms 
underlying the reported phenotype, precise conclusions cannot be drawn yet. 
Limitations such as damage caused by the invasiveness of the oxygen electrode 
cannot be rejected. Additionally, earlier studies have indicated the role of NO as a 
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modulator of the ACTZ-induced CBF response (Tuettenberg et al., 2001). 
Interestingly, the NO pathway appears to be compromised in BDL animals due to 
hyperammonemia (Balasubramaniyan et al., 2012) and it could therefore be a 
limiting factor in fully restoring cerebral perfusion via ACTZ (PO2 of treated BDL 
animals is still on the lower range of normal PO2). CBF will be further investigated in 
an MRI study, examining baseline perfusion, effectiveness of ACTZ and sildenafil in 
increasing CBF as well as integrity of neurovascular coupling in animal models of HE 
(beyond the scope of this study). 
 
The role of ammonia in interfering with brain oxygenation was also investigated, by 
treating BDL rats with OP, a drug known to lower systemic and brain ammonia 
(Davies et al., 2009). OP treatment significantly improved PO2 of BDL animals, 
suggesting that ammonia is indeed responsible for the reported phenotype. The 
exact pathway by which ammonia affects brain oxygenation is unknown, however, a 
recent study has revealed that hyperammonemia contributes to endothelial nitric 
oxide synthase (eNOS) downregulation through induction of inflammation and 
increased production of asymmetric-dimethylarginine, an endogenous inhibitor of 
eNOS (Balasubramaniyan et al., 2012). NO plays an important role in regulating 
blood flow and preventing vascular and endothelial dysfunction, which could 
contribute to HE. Reduction in ammonia with OP restored eNOS activity, improving 
NO metabolism (Balasubramaniyan et al., 2012). 
 
In BDL animals, electron microscopy studies reported collapsed microvessel with 
moderate perimicrovessel oedema (Wright et al., 2007), which is possibly a major 
	 53	
contributor in the reduced CBF reported in HE patients. Cytotoxic oedema arising 
due to hyperammonemia could result in an extrinsic compression of capillaries (a 
phenotype also seen in kidneys due to ischemia (Johnston and Latta, 1977)) and 
therefore compromise baseline blood flow. However, a more precise method such as 
in vivo two-photon microscopy should be performed in order to further investigate the 
cerebrovascular structure of these animals. Additionally, pericytes that are contractile 
cells on capillaries, which might be involved in CBF regulation (Fernandez-Klett et 
al., 2010), are believed to die after ischemia-induced constriction (partly due to 
glutamate) or oxidative stress (Yemisci et al., 2009). These cells die in rigor and 
produce long-lasting decrease of capillary constriction and blood flow (as well as 
BBB breakdown) (Hall et al., 2014, Hauck et al., 2004), contributing to neuronal 
damage, which could also occur during HE and be responsible for the reported 
phenotype. Pericytes have not been studied extensively in the field of HE and it will 
therefore be essential to investigate their role in more depth. While the above 
proposed factors in combination with the impaired NO metabolism, could be resulting 
in a higher vascular tone, vasodilation due to CO2 was preserved in BDL animals, 
suggesting intact cerebrovascular reactivity and capacity for blood vessels to dilate. 
 
Another possible mechanism by which increased ammonia could be compromising 
brain PO2 is via impairment of brain energy metabolism. Evidence exists pointing 
towards lactate as an important energy substrate (further investigated in Chapter 3) 
as well as a mediator of vasodilation (Hein et al., 2006, Gordon et al., 2008). 
Furthermore, high ammonia concentrations interfere with mitochondrial functionality, 
by inhibiting enzymes such as α-ketoglutarate dehydrogenase, pyruvate 
dehydrogenase and isocitrate dehydrogenase, which could profoundly affect the 
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operational rate of the tricarboxylic acid cycle and subsequently the electron 
transport chain. Additionally it can interfere with the malate-aspartate shuttle, which 
is the principal mechanism for the transfer of reducing equivalents from the cytosol 
into mitochondria for oxidative phosphorylation, and it can therefore alter further the 
normal operation of the electron transport chain (Rama Rao and Norenberg, 2012). 
Furthermore, studies using chronic hyperammonemic mice indicated a progressive 
inhibition of cytochrome C oxidase (complex IV of electron transport chain, ETC) 
activity and mRNA levels of its subunit II (Rao et al., 1997). Another possible 
mechanism for impaired energy metabolism in HE and hyperammonemia is the 
mitochondrial permeability transition pore. This leads to a collapse of the 
mitochondrial (mainly astrocytic) inner membrane potential that is created by the 
pumping out of protons by the electron transport chain. Loss of the membrane 
potential leads to osmotic swelling of the mitochondrial matrix, defective oxidative 
phosphorylation, decrease of ATP synthesis, and the production of ROS (Rama Rao 
and Norenberg, 2012). This in combination with a possible impairment in lactate 
production and release, could be setting the brain in a dysmetabolic state, with 
alterations in neuronal activity, oxygen consumption and therefore changes in CBF 
and oxygen supply, which improves when hyperammonemia is resolved. The 
proposed hypothesis of decrease demand of oxygen by cells followed by decreased 
supply, suggests that if oxygen is not used then its delivery will be altered 
accordingly, similar to the Hebbian synapse theory (“if you don’t use it, you lose it”). 
However, further work is required to support this hypothesis. 
 
In conclusion, the results presented in this Chapter suggest that HE is associated 
with reduced brain tissue PO2, which is independent of systemic hypotension, with 
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ammonia playing a key role. While the exact mechanism of the reported phenotype 
is still unclear, it is proposed that ammonia acts by diminishing brain metabolic 
activity and oxygen consumption, as well as increasing vascular tone [via NO, 
lactate, mitochondrial deficiency (planned to be investigated in more depth), 
compressed blood vessels] with secondary effects on CBF. The hypoxic conditions 
reported in this study are sufficient to trigger astrocytic activation, (Angelova et al., 
2015) as well as neuronal death (Banasiak and Haddad, 1998) and are hypothesised 
to contribute to the pathogenesis of HE. 
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Chapter 3: Ammonia mediates cortical hemichannel 
dysfunction and impairs lactate release in rodent models of 
chronic liver disease with minimal hepatic encephalopathy  
 
3.0  Introduction 
 
Several hypotheses regarding the pathogenesis of HE have been proposed and 
numerous factors have been suggested as key players in HE, including: 
inflammation (Jalan et al., 2004b), oxidative stress (Bosoi and Rose, 2013b), 
impaired brain energy metabolism (Rao and Norenberg, 2001) and (the most 
common one) the neurotoxic effects of ammonia (Shawcross and Jalan, 2005). 
Recent evidence demonstrated that astroglial lactate production and release in 
cortical cultures and in the somatosensory cortex of anesthetised rats is facilitated in 
the presence of ammonia (Lerchundi et al., 2015). This appears to be due to 
acidification of the mitochondrial matrix resulting in a direct inhibition of mitochondrial 
pyruvate uptake. Increased brain lactate levels have also been reported in 
hyperammonemic conditions such as in ALF, which is thought to be due to inhibition 
of the tricarboxylic acid cycle enzyme α-ketoglutarate dehydrogenase, suggesting a 
reduction in oxidative metabolism (Rose et al., 2007). Results described in the 
previous Chapter revealed compromised cerebral PO2 in animal models of HE, with 
ammonia playing a key role. Thus, it was then determined whether significant 
changes in brain lactate metabolism develop in conditions of long-term CNS 
exposure to increased ammonia concentration, such as that seen during CLD or HE.  
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Astrocytes, one of the most numerous type of glial cell in the CNS, are thought to 
play an important role in HE pathogenesis. The astrocytic dysfunction developing 
during the progression of the disease could precipitate neuronal pathology, leading 
to neurological impairment. Astrocytes are extensively connected by GJ formed of 
connexins, which also exist as functional hemichannels allowing effective transfer of 
ions, metabolic substrates and signalling molecules across the plasma membrane 
(Bennett et al., 2003). Under normal physiological conditions, hemichannels are 
either closed (Contreras et al., 2003) or in a flickering state (Bukauskas and 
Peracchia, 1997). In certain pathological conditions, such as epilepsy and ischemia, 
significant changes in astroglial structure and function may occur, which are 
associated with changes in connexin hemichannel function, affecting coupling within 
the astroglial networks and their communication with other brain cells (Giaume et al., 
2010). It is therefore hypothesised, that in HE, connexin hemichannel dysfunction 
contributes to the development of its neurological features. 
 
There is recent evidence that hemichannels may function as a conduit of lactate 
transport across the membrane (Karagiannis et al., 2016). Therefore, it was next 
investigated whether connexin hemichannel expression and hemichannel-mediated 
release of lactate are altered in animal models of HE. OP (OCR-002; Ocera 
Therapeutics, CA, USA) was applied in this study, as described in Chapter 2, as an 
experimental ammonia-lowering treatment. The data obtained demonstrate that, in 
HE, ammonia mediates cortical hemichannel dysfunction associated with a 
significant reduction in hemichannel-mediated lactate release, whereas no significant 
alterations are observed in the cerebellum.  
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3.1  Materials and Methods 
 
All the experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 (ASPA) revised according to the European Directive 
2010/63/EU and the UK Home Office (Scientific Procedures) Act (1986) with project 
approval from the Institutional Animal Care and Use Committee.  
 
3.1.1 Animal models  
 
Male Sprague-Dawley rats (body weight ~350-400g) were obtained from a 
commercial supplier (Charles Rivers Laboratories, Inc.). 
 
BDL surgery: 30 rats underwent BDL surgery as described in detail in section 2.1.1. 
 
Non-cirrhotic hyperammonemia condition: 32 rats were administered high 
ammoniagenic diet (HA). The amino acid recipe used for a stock of ~100g was: 15g 
leucine, 7.7g phenylalanine, 7g glutamate, 10g alanine, 4.4g proline, 5.8g threonine, 
11g aspartate, 5g serine, 4.8g glycine, 3.3g arginine, 9.6g lysine, 8.4g histidine, 3g 
tyrosine, 1.5g tryptophan and 10.6g valine. 25 g of this mix (mixed 1:5 with standard 
rodent chow powder) was freshly prepared daily with water in a mash form and rats 
were given free access to it for 5 days. The recipe approximates the amino acid 
composition of a rodent haemoglobin (Riggs, 1963), mimicking the effect of 
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gastrointestinal bleeding, which is known to result in systemic hyperammonemia 
(Balata et al., 2003). 
 
Ornithine Phenylacetate (OP) treatment: 24 BDL-operated animals were treated with 
OP as described in detail in section 2.1.1. 
 
Blood and brain tissue were collected under terminal isoflurane anaesthesia. Plasma 
biochemistry was performed using a Cobas Integra II system (Roche Diagnostics). 
 
3.1.2 In vitro slice preparation 
 
Rats were humanely sacrificed by isoflurane inhalation overdose. After cardiac 
perfusion with chilled (4°C) artificial cerebrospinal fluid (aCSF, 124 mM NaCl, 3 
mM KCl, 2 mM CaCl2, 26 mM NaHCO3, 1.25 mM NaH2PO4, 1 mM MgSO4, 10 mM 
D-glucose saturated with 95% O2, 5% CO2, pH 7.5, PCO2 35 mmHg), with an 
additional 9mM Mg2+, the brain was rapidly removed and placed in a bath of chilled 
(4-6°C) aCSF. 300 µm coronal cortical and cerebellar slices were cut using a 
vibrating microtome. The slices were recovered in oxygenated (95% O2, 5% CO2) 
aCSF at room temperature for 30 min.  
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3.1.3 Quantitative real-time PCR 
 
Quantitative real-time PCR (RT-qPCR) was used to determine the level of connexin 
RNA expression in the cortex of Sham (n=5) and BDL rats (n=6). 1µg of extracted 
and purified RNA was reverse transcribed using the QuantiTect Reverse 
Transciption Kit (Qiagen) as per manufacturer’s protocol. PCR reactions were 
performed in 20µl volumes using the TaqMan Universal Master Mix II with the final 
volume of 9µl cDNA, equivalent to 1µg RNA, sample template per reaction. PCR 
reactions were performed in duplicate using the TaqMan assay as detection method 
and an Applied Biosystems 7500 Real Time PCR system (Applied Biosystems Inc., 
Austin, TX, USA). Relative quantification values for gene expression were calculated 
using the comparative ΔΔCt method normalising to Ubiquitin C (Rn01789812_g1, 
88 bp amplicon length, Life Technologies). The TaqMan assays used were: 
connexin-43 (Rn01433957_ml), connexin-36 (Rn00439121_m1), connexin-30 
(Rn02042582_s1) and connexin-26 (Rn00691548_m1), all purchased from Thermo 
Fisher scientific.  
 
3.1.4 Western blot  
 
Proteins (30 µg) extracted from the cortices of 5 Sham-operated, 6 BDL, 6 HA and 5 
BDL-OP-treated rats were separated by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis on a 4% to 12% Bis-Tris NuPAGE gel (Invitrogen) and transferred to 
nitrocellulose membranes. Membranes were blocked with 5% Bovine Serum 
Albumin and incubated with antibodies against connexin-43 (Cell Signaling 
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Technology, 1:1000), connexin-36 (Santa Cruz, 1:1000), connexin-30 (Invitrogen, 1 
µg/mL) and connexin-26 (Thermo Fisher Scientific, 1 µg/mL). Detection of actin 
(Santa Cruz, 1:1000) was used to control for protein loading. Binding of antibody was 
detected using a horseradish peroxidase-conjugated secondary antibody (Goat anti-
rabbit or goat anti-mouse IgG-HPR, Santa Cruz, 1:10000) where appropriate and the 
SuperSignal Chemiluminescence Substrate for detection of horseradish peroxidase 
(Pierce). Densitometric analysis was performed using Kodak 1D image analysis 
software (Kodak, Rochester, NY). 
 
3.1.5 Measurements of lactate release using microelectrode biosensors  
 
Amperometric enzymatic biosensors were obtained from Sarissa Biomedical 
(Coventry, UK). The design and operation of the biosensors were described in detail 
previously (Llaudet et al., 2003, Tian et al., 2009). All sensors were operating against 
a reference electrode (Ag/AgCl) and had a linear response to lactate within the 
concentration range recorded in this study (Karagiannis et al., 2016). Further 
information on the principle of operation and response time is given in Figure 11A-C. 
To control for the release of non-specific electroactive interferants, a dual recording 
configuration was used. In every recording, a “null” sensor, lacking enzymes but 
otherwise identical, was used to measure current changes not associated with 
lactate oxidase activity, which were then subtracted from the current recorded by the 
lactate biosensor (Gourine et al., 2002) (Figure 12).  
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Figure 11: Response time, principles of lactate biosensor operation and the effect of 
OP on lactate biosensor detection system. A. A schematic drawing of the lactate 
biosensor assembly showing the enzymatic biolayer, which surrounds the tip of the platinum 
(Pt) wire. B. Enzymatic reaction taking place in the biolayer of the sensor. C. Expanded 
portion of the lactate calibration trace illustrating the response time of the lactate biosensor. 
Note that the sensor responds immediately when lactate solution is starting to enter the 
calibration chamber. D. Raw traces illustrating lactate biosensor current responses to lactate 
(100 µM) when calibrated in control artificial cerebrospinal fluid (aCSF), and in the presence 
of ornithine phenylacetate (OP, 1:50 dilution of the stock solution of 0.1g/ml; concentration 
applied is similar to the concentration estimated to be reached in a 300 g rat following IP 
injections). Bottom: Representative trace from the recordings obtained in the cerebral cortex 
of a BDL rat showing the effect of OP on lactate tone. Grey shading indicates period of OP 
application. 
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The sensors were calibrated directly in the slice chamber immediately before and 
after every recording by application of 100 µM of lactate (Figure 12). To convert 
changes in the biosensor current to changes in lactate concentration, an average of 
sensor calibrations before and after the recording were used. For each of the 
recordings, a slice was transferred into the recording chamber and superfused with 
aCSF at 35°C (3 ml min-1). Sensors were initially placed in the chamber having no 
contact with the cortical or cerebellar slice. Once a steady-state baseline was 
achieved, the sensors were laid flat in direct contact with the surface of the slice 
(Figure 12), revealing tonic lactate release which stabilised within ~15 min. Hypoxic 
conditions, known to increase both lactate production due to inhibition of oxidative 
phosphorylation and the opening probability of connexin hemichannels (Orellana et 
al., 2010, Karagiannis et al., 2016), were induced for 2-4 min by replacement of 
oxygen in the medium with nitrogen (perfusion of the chamber with aCSF saturated 
with 95% N2/5% CO2) (Huckstepp et al., 2010). As detection of lactate by the 
biosensors requires oxygen (Figure 11B) (Turovsky et al., 2015), the effect of 
hypoxia was determined by measuring the peak lactate release upon re-oxygenation 
(Figure 12) as described in detail previously (Turovsky et al., 2015, Karagiannis et 
al., 2016). Once the baseline was restored, Ca2+-free aCSF (with the addition of 1 
mM EGTA) was applied for 20 min as the second stimulus known to increase the 
opening probability of certain membrane channels, including connexin hemichannels 
(Muller et al., 2002). There is no prior evidence that Ca2+-mediated increases in 
mitochondrial NADH influence cytosolic NAD+/NADH homeostasis and therefore 
lactate production (Marcu et al., 2014). These stimuli were reapplied in the presence 
of connexin hemichannel blockers carbenoxolone (CBX, 100 µM; Sigma) or 5-Nitro-
2-(3-phenylpropylamino)benzoic acid (NPPB, 200 µM, Sigma) and an MCT blocker, 
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4-CIN (250 mΜ; Sigma). CBX, NPPB and 4-CIN were previously shown to have no 
effect on lactate biosensor detection system (Karagiannis et al., 2016).  
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Figure 12: Measuring release of lactate using microelectrode biosensors. 
Representative example of changes in the net lactate biosensor current (difference in 
current between lactate and null sensors) during calibration (100 µM lactate), after biosensor 
placement in direct contact with the surface of the cortical slice (recording tonic lactate 
release), in response to a hypoxic challenge (perfusion with aCSF saturated with 95% N2/5% 
CO2), and in response to lowering extracellular [Ca2+]. Peak hypoxia-induced lactate release 
is measured upon reoxygenation. Upper left: Schematic drawing of the dual recording 
configuration of lactate and null (control) biosensors placed on the surface of the brain slice. 
 
 
 
 
 
 
	 66	
3.1.6 Assessment of connexin-43 hemichannel function by dye loading of 
transfected HeLa cells 
 
For the assessment of hemichannel functionality (effectiveness of channel opening 
and closing) 200 µM fluorescent dye carboxyfluorescein (CBXF: 376 Da) was used. 
Connexin hemichannels are permeable to CBXF and can act as conduits of CBXF 
transfer across the membrane in accord with the concentration gradient of the dye. 
When the cells are exposed to a condition that triggers connexin opening (e.g. 0 
Ca2+ aCSF), CBXF enters the cells. The dye remains in the HeLa cells making them 
fluorescent under the microscope and the amount of fluorescence correlates with 
opening of hemichannels. Connexin-43 transfected HeLa cells (on coverslips) were 
subjected to CBXF for 5 min in Ca2+-free aCSF (positive control) or 5 mM ammonia 
aCSF. This was then followed by a wash of 30 min in standard aCSF. For analysis, 
40 cells were randomly chosen for each condition. Using ImageJ, an ROI was drawn 
around each cell body and the median pixel intensity for the cell was calculated. 
Background fluorescence was subtracted (Huckstepp et al., 2010). 
 
3.1.7 Assessment of cortical hemichannel function by dye loading 
 
Cortical slices from Sham-operated, BDL, HA and BDL-OP-treated rats were 
exposed to control aCSF with an addition of CBXF for 9 min resulting in background 
connexin-mediated dye loading, followed by perfusion with Ca2+-free aCSF without 
CBXF for 9 min resulting in CBXF unloading. Ca2+-free aCSF with CBXF was then 
applied for 4 min increasing the permeability of hemichannels and therefore resulting 
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in dye loading. Hypoxic conditions (without CBXF) were next applied to unload the 
slice and also to demonstrate bidirectional permeability of the channel to CBXF 
(Meigh et al., 2013). The same hypoxic stimulus was then re-applied in the presence 
of CBXF, resulting in dye loading. After application of each stimulus in the presence 
of CBXF, a further 5 min perfusion with aCSF containing CBXF, followed by a 10 min 
wash with normal aCSF was applied, enabling the channels to return to their 
physiological state. Images were taken using MiCAM-02 imaging system (SciMedia). 
Using ImageJ software, ROI were drawn around an area of the cerebral cortex 
(~3cm2) across layers I-III and the mean pixel intensities for the ROI were calculated. 
Background fluorescence was subtracted.  
 
3.1.8 Statistical analysis  
 
For the analysis of the RT-qPCR data, the intervals of confidence (95% IC) have 
been obtained by applying the general formula for the propagation of errors to the 
initial standard deviations of the duplicates measured for each sample (Chapman et 
al., 2012). Western blot data were normalised using the protocol of LI-COR 
Biosciences (Normalisation Accuracy for Western Blotting) and group data were 
compared using two-way ANOVA with Tukey post hoc test. Data obtained using 
biosensor recordings were analysed and presented non-parametrically using box 
and whisker plots (Figures 13-15A, 16A-C). For the comparisons between the 
experimental groups, Kruskal-Wallis test followed by Dunn’s post hoc test was 
applied. The peak hypoxia- or 0 Ca2+-induced lactate releases are presented as 
changes in release from the baseline (Figure 12). The effects of connexin blockers 
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are presented as % changes from the control responses recorded in the absence of 
the blockers and Wilcoxon signed rank test was applied for comparison. p values in 
Figures 13-15B,C indicate significance level of differences between the control 
responses and the responses recorded in the presence of the drugs. 
 
Data obtained in dye loading experiments were analysed using two-way ANOVA 
(Figure 18-19B, data normally distributed) followed by Tukey post hoc test or 
Wilcoxon signed rank test (Figures 19C-D, data not normally distributed), as 
appropriate. The biochemistry data was analysed using one-way ANOVA. Data are 
reported as mean±SEM. Differences with p value of <0.05 were considered to be 
significant. In all the experiments the ‘n’ number represents the number of animals. 
Sample sizes were calculated using Gpower 3 v3.1.9.2 
(http://www.gpower.hhu.de/en.html) (Faul et al., 2009); using a ‘means: Wilcoxon-
Mann-Whitney test (two groups)’ test, with a desired power of 90% and a 
significance level of 5%. The effect size varied between groups according to the 
preliminary data acquired during the study. Statistical analysis was performed using 
OriginPro 9.1 (OriginLab). 
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3.2  Results 
3.2.1 Biochemistry 
 
Plasma biochemistry and ammonia concentration were assessed in all groups of 
animals, indicating the same parameters described in Chapter 2 (Table 2-3). 
Additionally, rats fed with HA diet had similar plasma biochemistry to control rats. 
Plasma ammonia concentrations were significantly higher in BDL and HA rats when 
compared to Sham-operated animals (p<0.001) (Table 2-3). 
 
Parameters HA 
N numbers 22 
Ammonia, µmol/L 121±4** 
Albumin, g/L 30±0.4 
Total protein, g/L 51±1 
Bilirubin, µmol/L 4±0.3 
ALT, U/L 17±2 
 
Table 3: Plasma biochemistry of hyperammonemic (HA) rats. ALT: alanine 
aminotransferase. Data expressed as means±SEM, **p<0.001 compared to Sham group 
using one-way ANOVA. 
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3.2.2 Release of lactate in the cerebral cortex and cerebellum in animal 
models of HE  
 
In cortical slices of Sham-operated animals, enzymatic amperometric biosensors 
detected tonic lactate efflux of 335±10 µM (n=18). Recordings from cortical slices of 
BDL and HA rats showed lower tonic release of lactate of 203±6 µM (p=0.03, n=18) 
and 178±8 µM (p=0.005, n=16), respectively (Figure 13A). Increasing the 
permeability of connexin hemichannels by lowering [Ca2+]e (0 Ca2+ conditions) 
triggered similar increases in the release of lactate in Sham-operated rats (by 
43±3µM, n=15), BDL (by 38±4 µM; p=0.07, n=17) and HA animals (by 54±4 µM; 
p=0.5, n=16) (Figure 14A). Hypoxia facilitated release of lactate in cortical slices of 
Sham-operated rats (43±3 µM, n=18), but had no effect on lactate release in slices 
of BDL (1±0.8 µM; p<0.001, n=18) and HA animals (5±2 µM; p<0.001, n=16) (Figure 
15A). These results demonstrated impaired tonic and hypoxia-induced release of 
lactate in both animal models of HE. 
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Figure 13: HE is associated with a reduction in hemichannel-mediated release of 
lactate in the cerebral cortex. A. Summary data illustrating tonic release of lactate in 
cortical slices of Sham operated, BDL, HA, and BDL-OP treated rats. p values indicate 
differences from Sham-operated rats. B. Left: Summary data illustrating the effect of CBX 
(100 µM) on tonic release of lactate (expressed as percent change from the baseline) in 
cortical slices of Sham-operated, BDL, HA, and BDL-OP treated rats. Right: Representative 
recordings of lactate biosensor current showing changes in tonic release of lactate in 
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response to CBX application. p values indicate differences from the respective baseline. C. 
Left: Summary data illustrating the effect of NPPB (200 µM) on tonic release of lactate 
(expressed as percent change from the baseline) in cortical slices of Sham-operated, BDL, 
HA, and BDL-OP treated rats. Right: Representative recordings of lactate biosensor current 
showing changes in tonic release of lactate in response to NPPB application. p values 
indicate differences from the respective baseline. 
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Figure 14: Lactate release in response to lowering extracellular [Ca2+]. A. Summary 
data illustrating peak changes in lactate release in response to lowering [Ca2+]e in cortical 
slices of Sham-operated, BDL, HA, and BDL-OP treated rats. p values indicate differences 
from the responses recorded in Sham-operated rats. B. Left: Summary data illustrating the 
effect of CBX (100 µM) on the release of lactate facilitated in response to 0 [Ca2+]e 
(expressed as the percentage of the amount of lactate released in response to 0 [Ca2+]e in 
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the absence of CBX) in cortical slices of Sham-operated, BDL, HA, and BDL-OP treated 
rats. Right: Representative recordings of lactate biosensor current showing the effect of CBX 
on 0 [Ca2+]e -induced release of lactate. p values indicate differences between the responses 
recorded in the absence and presence of CBX. C. Left: Summary data illustrating the effect 
of NPPB (200 µM) on the release of lactate facilitated in response to 0 [Ca2+]e (expressed as 
the percentage of the amount of lactate released in response to 0 [Ca2+]e in the absence of 
NPPB) in cortical slices of Sham-operated, BDL, HA, and BDL-OP treated rats. Right: 
Representative recordings of lactate biosensor current showing the effect of NPPB on 0 
[Ca2+]e -induced release of lactate. p values indicate differences between the responses 
recorded in the absence and presence of NPPB. 
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Figure 15: HE is associated with a reduction of hypoxia-induced release of lactate. A. 
Summary data illustrating peak changes in lactate release in response to hypoxia (aCSF 
saturated with 95% N2/5% CO2) in cortical slices of Sham-operated, BDL, HA, and BDL-OP 
treated rats. p values indicate differences from the responses recorded in Sham-operated 
rats. B. Left: Summary data illustrating the effect of CBX (100 µM) on the release of lactate 
facilitated in response to hypoxia (expressed as the percentage of the amount of lactate 
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released in response to hypoxia in the absence of CBX) in cortical slices of Sham-operated, 
BDL, HA, and BDL-OP treated rats. Right: Representative recordings of lactate biosensor 
current showing the effect of CBX on hypoxia-induced release of lactate. Decrease in O2 
availability reduces biosensor current followed by a positive signal upon reoxygenation, 
which is used to estimate hypoxia-induced lactate release. p values indicate differences 
between the responses recorded in the absence and presence of CBX. C. Left: Summary 
data illustrating the effect of NPPB (200 µM) on the release of lactate facilitated in response 
to hypoxia (expressed as the percentage of the amount of lactate released in response to 
hypoxia in the absence of NPPB) in cortical slices of Sham-operated, BDL, HA, and BDL-OP 
treated rats. Right: Representative recordings of lactate biosensor current showing the effect 
of NPPB on the hypoxia-induced release of lactate. p values indicate differences between 
the responses recorded in the absence and presence of NPPB. 
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Figure 16: HE is not associated with alterations in lactate release in the cerebellum. A. 
Summary data illustrating tonic release of lactate in cerebellar slices of Sham-operated, BDL 
and HA rats. B. Summary data illustrating peak changes in lactate release in response to 
hypoxia (aCSF saturated with 95% N2/5% CO2) in cerebellar slices of Sham-operated, BDL 
and HA rats. C. Summary data illustrating peak changes in lactate release in response to 
lowering [Ca2+]e in cerebellar slices of Sham-operated, BDL and HA rats. p values indicate 
differences from the Sham-operated rats. 
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The same protocol was applied to record lactate release in cerebellar slices from 
Sham, BDL and HA animals. In Sham-operated animals biosensors detected tonic 
lactate efflux of 221±13 µM (n=13). In BDL and HA rats, the lactate tone recorded 
was 183±11 µM (n=16, p=0.2) and 211±9 µM (n=17, p=1) respectively, which was 
not significantly different from the Sham-operated animals (Figure 16A). Hypoxia-
induced no lactate release in cerebellar slices of Sham-operated rats (0±2 µM, 
n=12), and it was not different from the lactate release in slices of BDL (-5±1 µM; 
p=0.8, n=16) and HA animals (0±2 µM; p=0.3, n=13) (Figure 16B). Finally, 
increasing the permeability of connexin hemichannels by lowering [Ca2+]e triggered 
similar increases in the release of lactate in Sham-operated rats (by 39±13µM, 
n=13), BDL (by 32±1 µM; p=0.3, n=16) and HA animals (by 28±3 µM; p=0.1, n=16) 
(Figure 16C). These results demonstrated intact tonic and hemichannel-induced 
release of lactate in the cerebellum of both animal models of HE.  
 
Due to the cerebellar recordings from BDL and HA not being significantly different 
from the ones observed in the Sham-operated animals, the rest of the experiments 
were focused on the cerebral cortex.  
 
3.2.3 Ammonia lowering treatment restores cortical lactate release  
 
Experimental evidence further demonstrated that OP treatment of BDL rats restored 
tonic (374±11 µM; p=0.4, n=14) and hypoxia-induced (32±3 µM; p=0.6, n=14) lactate 
release similar to that recorded in cortical slices of Sham-operated animals (Figure 
13A, 15A). Direct application of OP on cortical slices of Sham-operated and BDL rats 
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had no effect on lactate release (Figure 11D). These results strongly suggest that 
high ammonia levels are responsible for the reduction in lactate release in the 
cerebral cortex of BDL animals. 
 
3.2.4 Impaired hemichannel function underlies reduced cortical lactate 
release in animal models of HE 
 
In cortical slices of Sham-operated animals, application of hemichannel blockers 
CBX (n=9) or NPPB (n=9) resulted in a significant reduction in lactate tone (Figure 
15B-C). Hemichannel blockade had no effect on lactate tone in cortical slices of BDL 
animals (Figure 13B-C). However, hemichannel blockade had an effect on lactate 
tone recorded in cortical slices of HA animals (CBX: n=10; NPPB: n=8) (Figure 13B-
C). CBX and NPPB reduced lactate tone in cortical slices of BDL animals treated 
with OP (CBX: n=10; NPPB: n=10) (Figure 13B-C). 
  
In cortical slices of Sham-operated (CBX: n=8; NPPB: n=6) and HA animals (CBX: 
n=10; NPPB: n=8), hemichannel blockade using CBX or NPPB abolished or 
significantly reduced the amount of lactate release facilitated in Ca2+-free conditions 
(Figure 14B-C). Smaller effect of hemichannel blockers on 0 Ca2+-induced release of 
lactate was observed in cortical slices of BDL rats (CBX: n=11; NPPB: n=9) (Figure 
14B-C). In conditions of OP treatment, when basal and evoked lactate release were 
restored in cortical slices of BDL rats, CBX (n=7) and NPPB (n=7) abolished the 
release of lactate triggered by 0 Ca2+ (CBX: n=7; NPPB: n=7); an effect similar to 
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that observed after application of hemichannel blockers in cortical slices of Sham-
operated animals (Figure 14B-C). 
 
Hypoxia-induced release of lactate recorded in cortical slices of Sham-operated 
animals was also abolished or markedly reduced by connexin hemichannel blockade 
(CBX: n=9; NPPB: n=7) (Figure 15B-C). CBX and NPPB had no significant effect on 
the release of lactate induced by hypoxia in cortical slices of BDL (CBX: n=13; 
NPPB: n=9) and HA rats (CBX: n=10; NPPB: n=12) (Figure 15B-C). In cortical slices 
of OP-treated BDL rats, the effects of CBX and NPPB were restored. CBX (n=8) and 
NPPB (n=7) effectively abolished hypoxia-induced lactate release in cortical slices of 
BDL rats treated with OP (Figure 15B-C).  
 
Application of MCT blocker, α-Cyano-4-hydroxycinnamic acid (4-CIN) had no 
significant effect on tonic release of lactate in cortical slices of Sham-operated (n=5) 
and BDL rats (n=5) (Figure 17A-B). Hypoxia-induced lactate release recorded in 
Sham-operated rats (n=5) was significantly reduced by 4-CIN, as reported previously 
(Karagiannis et al., 2016). In cortical slices of BDL rats (n=5) the effect of 4-CIN on 
hypoxia-induced release of lactate was found to be smaller (Figure 17A-B). 
 
These results demonstrate that connexin hemichannel blockade has no effect on the 
release of lactate in the cerebral cortex of BDL rats. This implies that the function of 
hemichannels, which act as conduits of lactate release (Karagiannis et al., 2016), is 
already compromised in the brains of these animals. These data also suggest that 
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cortical hemichannel dysfunction in the BDL animals is likely to be due to the actions 
of ammonia. 
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Figure 17: Monocarboxylate transporter (MCT) protein expression and functionality in 
cortical slices of Sham-operated and BDL rats. A. Summary data illustrating the effect of 
MCT blocker, 4-CIN (250 µM, Sigma) on tonic release of lactate (expressed as % change 
from the baseline) and release of lactate facilitated in response to tissue hypoxia and 0 
[Ca2+]e (expressed as the % of the amount of lactate released in response to hypoxia/0 
[Ca2+]e in the absence of 4-CIN) in cortical slices of Sham-operated, BDL, HA and BDL-OP 
treated rats. p values indicate differences between responses recorded in the absence and 
presence of 4-CIN. B. Representative recordings of lactate biosensor current showing the 
effect of 4-CIN on tonic as well as hypoxia- and 0 [Ca2+]e -induced release of lactate. C. 
Summary data illustrating means±SEM of the densitometry of MCT-1 protein levels, mainly 
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expressed in astrocytes (Chemicon International, 0.5 µg/mL) normalised to the expression of 
Actin, in cell lysates of the cerebral cortices of Sham-operated, BDL, HA and BDL-OP 
treated rats. Bottom: Representative immunoblots showing MCT-1 protein expression in 
cerebral cortices of Sham-operated, BDL, HA and BDL-OP treated rats. 
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3.2.5 Connexin-43 hemichannel-mediated dye loading in transfected HeLa 
cells exposed to high concentrations of ammonia  
 
HeLa cells transfected to express connexin-43, were kindly provided by Professor 
Nicholas Dale (Warwick University) for dye loading experiments. These experiments 
were performed at the beginning of this PhD study and the idea behind this work was 
to acquire data on whether the increased cerebral concentration of ammonia has an 
effect on the hemichannel functionality. If this hypothesis is correct then the 
fluorescence of the HeLa cells incubated with ammonia will be altered. 
 
The results obtained demonstrated that a 3 day incubation of the cells with 5 mM 
ammonia has an effect on the connexin-43 hemichannel opening as illustrated in 
Figure 18A. The opening of the channels after incubation with ammonia, exposed to 
0 Ca2+ stimulus, was significantly lower than in the control cells exposed to the same 
stimulus (0 Ca2+) (Figure 18B). This observation supports the idea that ammonia 
may directly alter connexin-43 functionality. Therefore, this hypothesis was further 
investigated using dye loading in slices of the cerebral cortex from Sham-operated 
rats and animal models of HE. 
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Figure 18: Ammonia impairs connexin-43 mediated dye loading in transfected HeLa 
cells. A. Dye loading assay demonstrating 0Ca2+-induced loading of carboxyfluorescein in 
HeLa cells expressing connexin-43, in the presence and absence of ammonia (NH4+) 
incubation. Cells incubated with ammonia (NH4+) for 3 days show lower uptake of the 
fluorescent dye compared to controls (no incubation). Scale bars 40 µm. B. Cumulative 
probability plots showing the average pixel intensity of connexin-43 transfected control HeLa 
cells (red) and HeLa cells treated for 3 days with 5 mM ammonia (green) and exposed to 0 
Ca2+ conditions. Each curve illustrates the averaged pixel intensity recorded from 40 cells. 
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3.2.6 Hemichannel-mediated dye loading in animal models of HE  
 
Membrane channel-mediated dye loading experiments were next performed in 
cortical slices to investigate brain hemichannel dysfunction in HE. In cortical slices of 
Sham-operated rats (n=10), significant background loading (14.3±0.4 A.U) was 
observed in control conditions when slices were perfused with aCSF containing 
CBXF (Figure 19A-B). Increasing the permeability of hemichannels by lowering 
[Ca2+]e in the absence of CBXF reduced slice fluorescence by 6.4±0.2 A.U. The 
same stimulus applied in the presence of CBXF significantly increased fluorescence 
by 16.9±0.6 A.U. Hypoxia-induced opening of hemichannels in the absence of CBXF 
resulted in dye unloading with fluorescence decreasing by 12.7±0.4 A.U. Addition of 
CBXF in conditions of hypoxia increased slice fluorescence by 13.9±0.4 A.U (Figure 
19B).  
 
In cortical slices of BDL rats (n=10) efficacy of CBXF dye loading and unloading was 
markedly reduced under all the conditions (Figure 19A-B). Cortical slices from HA 
rats (n=10) displayed background loading (Figure 19A-B) and 0 Ca2+ -induced 
unloading of 11.2±0.2 A.U (p=0.04) and 4.7±0.08 A.U (p=0.4) respectively (Figure 
19A-B). Addition of CBXF in 0 Ca2+ conditions increased fluorescence by 11.6±0.2 
A.U (p=0.004), similar to that observed in slices of Sham-operated animals. 
However, the effect of hypoxia was significantly reduced in slices of HA animals 
(unloading by 7.6±0.1 A.U, p<0.001; loading by 7.8±0.2 A.U, p<0.001) (Figure 19B). 
In cortical slices of BDL animals treated with OP, hemichannel-mediated CBXF dye 
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loading and unloading were similar to that observed in slices of Sham-operated 
animals (Figure 19A-B).  
 
Hemichannel blockade with CBX or NPPB effectively abolished CBXF dye loading 
and unloading in cortical slices of Sham-operated animals (Figure 19C-D). In cortical 
slices of BDL and HA rats, CBX and NPPB had no significant effect on dye loading 
and unloading (Figure 19C-D). In cortical slices of OP-treated BDL rats, the effects of 
CBX and NPPB on CBXF dye loading and unloading were similar to that observed in 
Sham-operated animals. (Figure 19C-D). Figures 19C-D illustrate changes in 
fluorescence (ΔFluorescence) following application of the hemichannel blockers, 
compared to the respective changes in fluorescence recorded in the absence of the 
blockers in slices of the same animal. Negative values show decreases in 
fluorescence while positive values illustrate higher fluorescence levels compared to 
the controls. 
 
These data show that the background activity and stimuli-evoked opening and 
closure of connexin hemichannels is impaired in BDL and HA rats. The efficacy of 
CBXF dye loading (and hence hemichannel functionality) is restored by OP 
treatment suggesting that the actions of ammonia are responsible for cortical 
hemichannel dysfunction in HE. 
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Figure 19: Impaired hemichannel-mediated dye loading reveals cortical hemichannel 
dysfunction in HE. A. Representative images of background loading with CBXF dye in 
cortical slices of Sham-operated, BDL, HA, and BDL-OP treated rats. White dashed lines 
depict the edge of each cortical slice. B. Fluorescence intensity changes in cortical slices of 
Sham-operated, BDL, HA, and BDL-OP treated rats in response to 0 [Ca2+]e and hypoxia in 
the absence and presence of CBXF in the medium. Application of 0 [Ca2+] aCSF or hypoxia 
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in the presence of CBXF resulted in dye loading and an increase in fluorescence, whereas 
application of these stimuli in the absence of CBXF resulted in dye unloading and a 
decrease in fluorescence. Insets: Schematic drawings of connexin hemichannel mediated 
dye loading and unloading. *p<0.05, **p<0.001 versus Sham-operated animals. C. Summary 
data illustrating the effect of CBX (100 µM) on fluorescence intensity changes 
(ΔFluorescence) in cortical slices of Sham-operated, BDL, HA, and BDL-OP treated rats 
induced by 0 [Ca2+]e and hypoxia in the absence and presence of CBXF in the medium. The 
data are presented as differences in fluorescence after CBX application compared with the 
respective fluorescence recorded in the absence of CBX. *p<0.05 for the effect of CBX on 
CBXF loading and unloading. D. Summary data illustrating the effect of NPPB (200 µM) on 
fluorescence intensity changes (ΔFluorescence) in cortical slices of Sham-operated, BDL, 
HA, and BDL-OP treated rats induced by 0 [Ca2+]e and hypoxia in the absence and presence 
of CBF in the medium. The data are presented as differences in fluorescence after NPPB 
application compared with the respective fluorescence recorded in the absence of NPPB. 
*p<0.05 for the effect of NPPB on CBXF loading and unloading. 
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3.2.7 Cortical connexin expression in animal models of HE 
 
The expression of the main astrocytic and neuronal connexins was next evaluated in 
animal models of HE used in this study. RT-qPCR was performed on mRNA 
extracted from the cerebral cortices of BDL and Sham-operated animals (Figure 20). 
The data were normalised against the housekeeping gene Ubiquitin C, which was 
chosen as the appropriate endogenous control gene after running a TaqMan Array 
Rat Endogenous Control Plate (Thermo Fisher scientific) testing 32 different genes.  
 
The relative expression of connexin-43, the most abundant astrocytic connexin was 
similar in the cerebral cortex of BDL rats (1.22, CI 0.23-0.29, n=6) and Sham-
operated animals (CI 0.16-0.19, n=5). No difference was observed in connexin-36 
(mainly neuronal) expression between the BDL (1.16, CI 0.16-0.19, n=6) and Sham-
operated animals (1, CI 0.18-0.22, n=5). Expression of connexin-30, the second 
main astrocytic connexin was found to be higher in the cortical tissue of BDL animals 
(1.49, CI 0.25-0.31, n=6) while no difference in connexin-26 expression was found 
(Sham-operated: 1, CI 0.24-0.32, n=5; BDL: 1.04, CI 0.18-0.21, n=6). 
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Figure 20: Cortical connexin RNA expression is not reduced in an animal model of 
HE. Relative expression (2-ΔΔCt) of connexin-43, connexin-36, connexin-30 and connexin-26 
mRNA normalised to the housekeeping gene, Ubiquitin C, in the cortex of Sham-operated 
and BDL animals. 
 
 
 
 
 
 
 
 
 
	 92	
Western blots were next performed on proteins extracted from the cerebral cortices 
of Sham-operated, BDL, HA and BDL-OP animals (Figure 21). No differences in 
cortical connexin-43, connexin-36 and connexin-30 expression was observed 
between Sham-operated, BDL, HA and OP-treated BDL animals. An increase in 
connexin-26 expression (p=0.03) was detected in BDL-OP rats compared to the BDL 
animals (Figure 21). Expression of MCT-1 was similar in all the experimental groups 
(Figure 17C). 
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Figure 21: Connexin protein expression in the cortex is not affected in HE. Top: 
Summary data illustrating means±SEM of the densitometry of connexin-43, connexin-36, 
connexin-30, and connexin-26 protein expression normalised to the expression of actin in 
cell lysates of the cerebral cortices of Sham-operated, BDL, HA, and BDL-OP treated rats. 
Bottom: Representative immunoblots showing connexin-43, connexin-36, connexin-30, and 
connexin-26 protein expression in cerebral cortices of Sham-operated, BDL, HA, and BDL-
OP treated rats. The p value indicates the difference in expression level between the BDL 
and BDL-OP treated groups. 
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3.3  Discussion 
 
Astrocytes represent an important source of lactate, which contributes to the 
extracellular pool of readily available metabolic substrates taken up by neurons to 
fuel their activity (Pellerin and Magistretti, 1994). While previously, lactate transport 
across the cell membranes was thought to be achieved solely via operation of 
monocarboxylate transporters (MCTs), a recent study (Karagiannis et al., 2016) 
demonstrated the role of connexin hemichannels as equally important conduits of 
lactate release. 
 
In animal models of ALF and patients, an increase in brain lactate concentration has 
consistently been reported (Rose, 2010). Concentrations of lactate in the CSF were 
also found to be elevated in cirrhotic patients but only in severe cases of HE (Yao et 
al., 1987). The BDL and HA rats used in these experiments are models of mHE 
(Butterworth et al., 2009). In contrast to the existing evidence suggesting that brain 
lactate concentrations are increased in patients with ALF (Bernal, 2010), the 
experiments described in this thesis demonstrated that the development of HE in 
rats is associated with a significant reduction in tonic and stimulated release of 
lactate in the cerebral cortex, whereas no marked changes were observed in the 
cerebellum. Additionally, hypoxia did not induce lactate release in the cerebellum of 
Sham-operated or diseased animals. The differences observed in the cortex and 
cerebellum can be explained by the heterogeneity of astrocytes present in each 
brain region. Detailed electrophysiological studies have revealed that protoplasmic 
and fibrous astrocytes in the cortex (as well as astrocytes in different brain regions) 
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express different levels and types of ion channels, such as K+ channels, than 
Bergmann glial in the cerebellum (Butt and Kalsi, 2006, Oberheim et al., 2012). This 
can result in subtle differences in electrophysiological properties, including resting 
membrane potentials. While it is still unclear whether heterogeneity exists with 
regard to the number of functional hemichannels within the different classes of 
astrocytes, evidence exists indicating regional differences in the shape of astrocytic 
syncytium and level of coupling by GJ (Kettenmann and Verkhratsky, 2011). Finally, 
studies have revealed that in the cerebellum, due to the morphology and structural 
arrangement of Purkinje neurons and astrocytes, Bergmann glial cells are in more 
intimate arrangement to synapses. This could explain the inability to record a 
hypoxia-induced lactate release in the cerebellum. It is possible that due to the 
astrocytes being in such close proximity to synapses, lactate released as a product 
of the hypoxic stimulus is taken up by neurons more effectively than in the cortex, 
which results in no recorded increase in extracellular lactate concentration. 
 
In the cortex, blockade of connexin hemichannels was found to be effective in 
reducing lactate release in Sham-operated and HA animals but was ineffective in 
BDL rats, suggesting that the reduction in hemichannel-mediated lactate release in 
BDL animals is due to a combination of pathological factors (e.g. inflammation, 
oxidative stress).   
 
Increased lactate production by astrocytes appears to be essential for the recovery 
of synaptic function during re-oxygenation after hypoxia (Schurr et al., 1997). It was 
found that hypoxia-induced lactate release was significantly lower in the cerebral 
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cortex of BDL and HA rats compared to control animals and this was unaffected by 
the hemichannel blockers indicating hemichannel dysfunction. The observed 
decrease in extracellular lactate is likely due to impaired release from astrocytes 
although increased neuronal activity and therefore lactate consumption cannot be 
excluded. The observation of Bosoi et al., (Bosoi et al., 2014) showing higher total 
brain lactate of BDL rats using NMR spectroscopy seems to contradict the reported 
data. Bosoi and colleagues suggested that increased lactate contributes to the 
pathogenesis of brain oedema (cytotoxic), and may imply that the observed increase 
in total brain lactate is due to its intracellular accumulation. If the rate of lactate 
production and glymphatic clearance (Lundgaard et al., 2016) is not affected, 
intracellular retention of lactate would explain higher concentration of this metabolite 
as measured by NMR spectroscopy (Bosoi et al., 2014) and would be in full 
agreement with the data showing impairment of hemichannel-mediated release in 
HE.   
 
High concentration of ammonia can potentially generate significant pH changes, 
which can have various effects on many pH sensitive membrane channels, including 
hemichannels. The pH sensitivity of hemichannels is known as the chemical gate, 
which is the phenomenon of hemichannel blockade when intracellular pH (pHi) 
decreases (Duffy et al., 2002). This provides one potential mechanism, which might 
be responsible for impaired hemichannel-mediated lactate release in HE.  
 
Hemichannel functionality was also examined using the dye loading method. Some 
differences between the data obtained using biosensor recordings and this technique 
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could be due to the fact that CBXF is not identical in terms of the molecular structure 
and size to lactate. Additionally, lactate could be released through specific connexin 
hemichannels, whereas CBXF is small enough to pass through the majority of 
hemichannels expressed by both astrocytes and neurons. While induction of hypoxia 
targets predominantly astroglial hemichannels (Orellana et al., 2010), the rest of the 
conditions are not cell specific and conclusions on affected cell types cannot be 
drawn from the results obtained using dye loading experiments.  
 
The experimental stimuli used (0 Ca2+ and hypoxia) are known to increase the 
permeability of hemichannels, possibly by affecting various protein bonds resulting in 
conformational changes (Muller et al., 2002). Dye loading experiments clearly 
demonstrated a marked reduction in fluorescent dye uptake and release in cortical 
slices of BDL and HA rats compared to Sham-operated animals (the differences 
were more profound when hypoxia was used as a stimulus), suggesting reduced 
bidirectional permeability of hemichannels in these animal models of HE. 
Hemichannel blockade had no effect on fluorescent dye uptake in BDL and HA rats 
providing additional evidence that the function of these channels is already 
compromised in HE. Ammonium ions may cause structural alterations to the 
connexin proteins, by interacting with various amino acid side chains, which could 
affect gating of the channel. However, since hemichannels have a relatively short life 
cycle and are recycled frequently, the observed changes in hemichannel functionality 
appear to be reversible with OP treatment.  
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In CLD, hyperammonemia is believed to impair mitochondrial function and induce 
astroglial dysfunction, which is associated with altered neurotransmitter recycling 
leading to neuronal damage (Bosoi and Rose, 2009). Ammonia may also interfere 
with cell energy metabolism in several ways. There is recent evidence suggesting 
that in astrocytes, ammonia may divert the flux of pyruvate to lactate production, 
contributing to the net aerobic lactate production (Lerchundi et al., 2015). However, 
the effects of chronic ammonia exposure on astrocytes are unknown. The role of 
ammonia was investigated by treating BDL rats with OP, a drug known to lower 
systemic and brain ammonia (Davies et al., 2009). OP treatment improved the 
neurochemical phenotype of BDL animals by restoring the tonic and stimulated 
connexin hemichannel-mediated lactate release. Furthermore, hemichannel 
blockade became effective following OP treatment, suggesting that ammonia is 
indeed responsible for hemichannel dysfunction observed in this model. 
 
Cytotoxic brain oedema observed in BDL animals is attenuated by ammonia-
lowering treatments such as the one used in this study (Bosoi et al., 2011, Davies et 
al., 2009). The effect of cell swelling on hemichannel function is poorly understood. 
Ye et al., (Ye et al., 2009) showed that astrocytes obtained from connexin-43 knock-
out animals developed cell swelling as efficiently as the wild type animals when 
exposed to a hypotonic solution suggesting that hemichannels do not play a 
significant role in this process although evidence to the contrary exists (Quist et al., 
2000).  
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On further examination of the expression profile of key astroglial and neuronal 
connexins in the animal models of HE used in this study, no significant differences 
were observed. This suggests that HE is associated with altered hemichannel 
function but not with changes in connexin expression. The upregulated expression of 
connexin-26 observed in the BDL-OP animals is not prominent enough to explain the 
marked improvement observed in the lactate measurements and dye loading 
experiments. Additionally, no changes were observed in the expression of the main 
astroglial lactate transporter MCT-1 in the models of HE used in this study. No effect 
of 4-CIN, a MCT blocker, on lactate release was observed in cortical slices of Sham-
operated and BDL animals. Hypoxia-induced lactate release in Sham-operated rats 
was significantly reduced by the application of 4-CIN, as demonstrated in the 
previous study (Karagiannis et al., 2016).  
 
Depletion of lactate as one of the key readily available metabolic substrates may 
have important neurological consequences particularly in patients with advanced 
cirrhosis given the fact that these patients display evidence of cerebral 
vasoconstriction (Guevara et al., 1998), which is associated with impaired cerebral 
autoregulation, an important mechanism which ensures constant CBF (Larsen et al., 
1995). Clinical consequences of this may be relevant during liver transplantation, 
where further reductions in CBF have been observed during the anhepatic phase of 
transplantation and may contribute to post-transplant neurologic dysfunction (Philips 
et al., 1998). Evidence for critical reduction in cerebral oxygenation was obtained in 
the majority of patients with acute-on-chronic liver failure who had poor neurologic 
outcome supporting the hypothesis that the brain energy metabolism is critically 
compromised in cirrhosis and further perturbations as demonstrated in this Chapter 
	 100	
may be clinically deleterious (Sawhney et al., 2016). The data indicating an impaired 
hemichannel-mediated lactate release and tissue hypoxia, in combination with these 
observations could help to explain the severe neurological manifestations in patients 
with HE. As ammonia is central in causing this dysfunction, the potential clinical 
implications involve the use of ammonia lowering treatments as the main therapeutic 
strategy, as well as attempts to increase cerebral oxygenation in order to preserve 
the neuronal function. 
 
In conclusion, the results of the present study suggest that HE is associated with 
cortical hemichannel dysfunction, with ammonia playing a key role. The data provide 
evidence of a potential neuronal energy deficit due to impaired hemichannel-
mediated lactate transport between astrocytes and neurons as a possible 
mechanism underlying pathogenesis of HE.   
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Chapter 4: Ammonia mediates alterations in cortical 
extracellular glutamate concentration in rodent models of 
chronic liver disease with minimal hepatic encephalopathy 
 
4.0  Introduction 
 
Ammonia is a ubiquitous by-product of nitrogen metabolism and the primary source 
of ammonia production is the gut. This takes place in the enterocytes and the 
ammonia-generating intestinal bacteria through the enzyme PAG, which catalyses 
deamination of glutamine to glutamate (Kato et al., 1992). Ammonia is therefore 
linked to the glutamate-glutamine cycle while its toxicity has been reported to be 
closely associated with the altered glutamatergic system (Bobermin et al., 2015, 
Gorg et al., 2010, Montana et al., 2014, Rose, 2006).  
 
Derangements of neurotransmitter systems have been suggested to play a 
significant role in the pathogenesis of HE (Butterworth, 2014). Glutamate is the major 
excitatory neurotransmitter in the mammalian brain and alterations in its homeostasis 
could lead to altered signal transduction as well as deleterious effects on the 
neurons, since high concentrations of glutamate are neurotoxic (Cooper, 2001). A 
glutamate-glutamine metabolic cycle exists between astrocytes and neurons and its 
role is to re-cycle glutamate that has been released from neurons, preventing 
neuronal over excitation (Cooper, 2001). Under normal conditions, glutamate 
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released by presynaptic neurons induces signalling through glutamate receptors. 
Astrocytic glutamate transporters, EAAT1/EEAT2 in humans and GLT-1/GLAST in 
rodents, take up the excess glutamate and it is then converted to glutamine by the 
GS enzyme, preventing glutamate accumulation (Bosoi and Rose, 2013a, 
Kimelberg, 2005). Glutamine is then transported to neurons via glutamine 
transporters, where it is hydrolysed back to glutamate (Broer and Brookes, 2001). 
 
An increase in extracellular glutamate has been documented in the rat cerebellum 
following portocaval anastomosis and has been described to occur as a result of 
decreased expression of astrocytic glutamate transporters, GLT-1 and GLAST 
(Suarez et al., 2000). Experimental studies described in this Chapter investigated 
whether glutamate release is altered in the cortex and cerebellum of animal models 
of CLD with mHE. In order to explore the role of ammonia, OP was applied as an 
experimental ammonia-lowering treatment (described previously in Chapter 2). The 
data obtained demonstrate that, in CLD, the actions of ammonia lead to a significant 
elevation of cortical extracellular glutamate, which may contribute to the 
development and pathogenesis of HE. 
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4.1  Materials and Methods 
 
All the experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 (ASPA) revised according to the European Directive 
2010/63/EU and the UK Home Office (Scientific Procedures) Act (1986) with project 
approval from the Institutional Animal Care and Use Committee.  
 
4.1.1 Animal models  
 
The animal models used in this study (BDL, HA and OP-treated BDL rats) have 
already been described in detail in Chapter 3.  
 
4.1.2 In vitro slice preparation 
 
In vitro slices were performed as described in section 3.1.2. 
 
4.1.3 Measurements of glutamate release using microelectrode biosensors  
 
Glutamate biosensors were used in the same way as the lactate biosensors, the 
operation of which is described fully in section 3.1.5. The design and operation of 
glutamate biosensors were described in detail previously (Tian et al., 2009). All 
sensors were operating against a reference electrode (Ag/AgCl) and had a linear 
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response to glutamate within the concentration range recorded in this study (Figure 
22).  
 
 
Figure 22: Representative calibration curve and sample responses of the glutamate 
biosensor showing a linear response to glutamate applied within the concentration 
range recorded in this study. 
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To control for the release of non-specific electroactive interferants, a dual recording 
configuration was used. In every recording, a “null” sensor, lacking enzymes but 
otherwise identical, was used to measure current changes not associated with 
glutamate oxidase activity, which were then subtracted from the current recorded by 
the glutamate biosensor (Gourine et al., 2002, Gourine et al., 2008) (same as lactate 
recordings in Figure 12). 
 
In these experiments, the sensors were calibrated directly in the slice chamber 
immediately before and after every recording by application of 10 µM of glutamate. 
To convert changes in the biosensor current to changes in glutamate concentration, 
an average of sensor calibrations before and after the recording were used.  
 
4.1.4 Quantitative real-time PCR 
 
The protocol used for the quantitative real-time PCR (RT-qPCR) is described in 
section 3.1.3. In this experiment, the RNA expression of the astrocytic glutamate 
transporters, GLT-1 and GLAST, was examined in the cortex of Sham-operated 
(n=5) and BDL rats (n=6). Relative quantification values for gene expression were 
calculated using the comparative ΔΔCt method normalising to Ubiquitin C 
(Rn01789812_g1, 88 bp amplicon length, Life Technologies). The TaqMan assays 
used in this experiment were: GLT-1 (Rn00564705_m1, 92 bp amplicon length) 
and GLAST (Rn01402419_g1, 99 bp amplicon length) all purchased from Thermo 
Fisher scientific. 
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4.1.5 Western blot  
 
The western blot protocol described in section 3.1.4 was applied for the 
quantification of GLT-1 protein in the cortices of 5 Sham-operated, 6 BDL and 6 HA 
rats. Membranes were blocked with 5% Bovine Serum Albumin and incubated with 
antibodies against GLT-1 (EAAT-2, Abcam, 1:1000). Detection of α-Tubulin (Cell 
Signaling Technology, 1:1000) was used to control for protein loading. Binding of 
antibody was detected using a horseradish peroxidase-conjugated secondary 
antibody (Goat anti-rabbit IgG-HPR, Santa Cruz, 1:10000) and the SuperSignal 
Chemiluminescence Substrate for detection of horseradish peroxidase (Pierce). 
Densitometric analysis was performed using Kodak 1D image analysis software 
(Kodak, Rochester, NY). Due to the inability to obtain a good antibody for GLAST, 
western blots for this specific protein were not performed. 
 
4.1.6 Statistical analysis  
 
Data obtained using biosensor recordings were analysed and presented non-
parametrically using box and whisker plots (Figure 23-25A, 26). For the comparisons 
between the experimental groups, Kruskal-Wallis test followed by Dunn’s post hoc 
test was applied. The peak hypoxia- or 0 Ca2+-induced glutamate releases are 
presented as changes in the release from the baseline (Figure 24-25, 26B-C).  
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For the analysis of the RT-qPCR data the intervals of confidence (95% IC) have 
been obtained by applying the general formula for the propagation of errors to the 
initial standard deviations of the duplicates measured for each sample (Chapman et 
al., 2012). Western blot data were normalised using the protocol of LI-COR 
Biosciences (Normalisation Accuracy for Western Blotting) and group data were 
compared using two-way ANOVA with Tukey post hoc test.  
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4.2  Results 
4.2.1 Biochemistry 
 
Plasma biochemistry and ammonia concentration were assessed in all groups of 
animals, indicating the same changes as described in Chapter 2 (Table 2-3). Rats 
fed with HA diet had similar plasma biochemistry to control rats. Plasma ammonia 
concentrations were significantly higher in both BDL and HA rats when compared to 
Sham-operated animals (p<0.001) (Table 2-3). 
 
4.2.2 Release of glutamate in the cerebral cortex and cerebellum in animal 
models of HE  
 
In cortical slices of Sham-operated animals, enzymatic amperometric biosensors 
detected tonic glutamate efflux of 0.9±0.06 µM, (n=27). Recordings from cortical 
slices of BDL and HA rats showed markedly higher tonic release of glutamate of 
5.7±0.3 µM (p<0.001, n=28) and 7.3±0.4 µM (p<0.001, n=26) respectively (Figure 
23). 
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Figure 23: HE is associated with markedly higher glutamate tone in slices of the 
cerebral cortex. Summary data illustrating tonic release of glutamate in cortical slices of 
Sham operated, BDL, HA, and BDL-OP treated rats. p values indicate differences from the 
Sham-operated rats. 
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Increasing the permeability of connexin hemichannels by lowering [Ca2+]e did not 
trigger glutamate release in Sham-operated rats (by Δ0.3±0.1 µM, n=24), BDL (by 
Δ0.5±0.1 µM, p=0.7, n=27) or HA animals (by Δ0.3±0.2 µM, p=0.5, n=22) (Figure 
24). Hypoxia had a significant effect on extracellular glutamate only in cortical slices 
prepared from the brains of BDL (1.6±0.1 µM, p=0.02, n=28) and HA animals (5±0.3 
µM, p<0.001, n=27), but not in slices of Sham-operated rats (Δ0.3±0.03 µM, n=28) 
(Figure 25).  
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Figure 24: Glutamate release is not affected by lowering extracellular [Ca2+]. Summary 
data illustrating peak changes in glutamate release in response to lowering [Ca2+]e in cortical 
slices of Sham-operated, BDL, HA, and BDL-OP treated rats. p values indicate differences 
from the responses recorded in Sham-operated rats. 
 
 
Figure 25: Hypoxia increases the level of extracellular glutamate in the cerebral cortex 
in animal models of HE. Summary data illustrating peak changes in glutamate release in 
response to hypoxia (aCSF saturated with 95% N2/5% CO2) in cortical slices of Sham-
operated, BDL, HA, and BDL-OP treated rats. p values show differences from the responses 
recorded in Sham-operated rats. 
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The same protocol was applied in cerebellar slices to record glutamate levels in 
Sham-operated, BDL and HA animals. In Sham-operated animals biosensors 
detected tonic glutamate efflux of 26±2 µM (n=13). In BDL and HA rats, the 
glutamate tone recorded was 12±0.6 µM (n=16, p=0.3) and 18±1 µM (n=16, p=0.7) 
respectively (Figure 26A). Hypoxia-induced glutamate release in cerebellar slices of 
Sham-operated rats (20±2 µM, n=12), was significantly higher than that recorded in 
the cortex. However, it was not significantly different from the glutamate release 
measured in slices of BDL (10±0.8 µM; p=0.1, n=16) and HA animals (10±0.7 µM; 
p=0.2, n=14) (Figure 26B). Finally, increasing the permeability of connexin 
hemichannels by lowering [Ca2+]e had no effect on the release of glutamate in Sham-
operated rats (by Δ0.1±0.4 µM, n=12), BDL (by Δ0.01±0.2 µM; p=0.9, n=16) and HA 
animals (by Δ0.03±0.4 µM; p=0.7, n=16) (Figure 26C). These results demonstrated 
that extracellular level of glutamate is not affected in the cerebellum of both animal 
models of HE. Since no differences in glutamate level were observed in the 
cerebellum, the subsequent experiments focused on the glutamate recordings in the 
cerebral cortex.  
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Figure 26: HE is not associated with significant alterations in extracellular glutamate 
concentrations in the cerebellum. A. Summary data illustrating tonic release of glutamate 
in cerebellar slices of Sham-operated, BDL and HA rats. B. Summary data illustrating peak 
changes in glutamate release in response to hypoxia (perfusion of the slice with aCSF 
saturated with 95% N2/5% CO2) in cerebellar slices of Sham-operated, BDL and HA rats. C. 
Summary data illustrating peak changes in glutamate release in response to lowering [Ca2+]e 
in cerebellar slices of Sham-operated, BDL and HA rats. p values indicate differences from 
the Sham-operated rats. 
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4.2.3 Ammonia lowering treatment restores cortical glutamate release  
 
OP treatment of BDL rats lowered tonic (1.1±0.09 µM, p=0.4 [compared to Sham-
operated animals], n=15) and hypoxia-induced (Δ0.7±0.1 µM, p=0.4, n=15) 
glutamate release to concentrations similar to that recorded in Sham-operated 
animals (Figure 23, 25). Glutamate was not released due to lowering of [Ca2+]e 
(Δ0.40±0.14 µM, p=0.08, n=14) (Figure 24). These results suggest that high 
ammonia levels are responsible for the increase in glutamate release in the cerebral 
cortex of BDL animals. 
 
4.2.4 Cortical glutamate transporter expression in animal models of HE 
 
The expression of the main astrocytic glutamate transporters was next evaluated in 
animal models of HE used in this study. RT-qPCR was performed on mRNA 
extracted from the cerebral cortices of BDL and Sham-operated animals (Figure 27). 
The data were normalised against the housekeeping gene Ubiquitin C. The relative 
expression of GLT-1 was not significantly different between the BDL- (1.16, CI 0.23-
0.28, n=6) and Sham-operated animals (1, CI 0.24-0.31, n=5). No difference in 
GLAST expression was observed between the BDL- (1.23, CI 0.25-0.23, n=6) and 
Sham-operated rats (1, CI 0.03-0.02, n=5).  
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Western blots were performed on proteins extracted from the cerebral cortices of 
Sham, BDL and HA animals and no differences in cortical GLT-1 protein expression 
were observed between the groups (Figure 27).  
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Figure 27: Cortical glutamate transporter expression in animal models of HE. A. 
Relative expression (2-ΔΔCt) of GLT-1 and GLAST mRNA normalised to the housekeeping 
gene, Ubiquitin C, in the cortex of Sham-operated and BDL animals. B. Top: Summary data 
illustrating means±SEM of the densitometry of GLT-1 expression normalised to the 
expression of α-Tubulin in cell lysates of the cerebral cortices of Sham-operated, BDL and 
HA rats. Bottom: Representative immunoblots showing GLT-1 protein expression in 
cerebral cortices of Sham-operated, BDL and HA rats. 
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4.3  Discussion  
 
Glutamate is the major excitatory neurotransmitter in the mammalian brain and can 
be released from astrocytes via various mechanisms. Glutamate metabolism is 
highly compartmentalised and can be influenced by several factors (Orellana et al., 
2011). Glutamate is also used as a precursor for other neurotransmitters, such as 
GABA. As a result an alteration in glutamate metabolism could lead to transmitter 
imbalance in the brain as well as extracellular accumulation of glutamate and 
therefore excitotoxicity and neuronal death. 
 
Under pathological conditions, the parameters that can change include: a) the 
content (expression, synthesis, degradation) of the main proteins involved in 
glutamate neurotransmission, such as the enzyme glutamate synthase or GS, b) 
spatial membrane concentrations of receptors and transporters, c) the function of 
receptor and transporters which is modulated in different ways including 
phosphorylation and dephosphorylation, d) alterations in the release and uptake of 
glutamate; and finally e) alterations in any of the steps of signal transduction 
pathways associated with different types of glutamate receptors (Monfort et al., 
2002). There is evidence indicating that high levels of ammonia inhibit glutamate 
uptake (Chan et al., 2000), which could be caused by the reversal of glutamate 
transporters (Kosenko et al., 1994) or the involvement of other factors such as 
oxidative stress (Blanc et al., 1998b) or manganese (Rose et al., 1999) interfering 
with glutamate transport even in the absence of changes in transporter expression. 
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In the experiments described in this Chapter, an increase in tonic glutamate 
concentration was observed in the cortex (but not the cerebellum) of BDL and HA 
rats compared to the Sham-operated controls. Some differences between the cortex 
and cerebellum in terms of the extracellular glutamate concentrations recorded are 
expected as discussed in Chapter 3. Additionally, Bergmann cells express GLAST 
at very high levels, while cortical glial mainly express GLT-1. The different glutamate 
transporters could be associated with some differences in glutamate affinity or 
overall kinetics (Drejer et al., 1982), resulting in moderate regional differences in 
extracellular glutamate as shown here. The data illustrated in this Chapter are in 
agreement with the results of human studies showing increased glutamate in the 
CSF of patients with liver cirrhosis and HE (Weiss et al., 2016, Watanabe et al., 
1984). Astrocytes are essential players in both the glutamate recycling and 
metabolism, and the removal of ammonia via the enzyme GS (Michalak et al., 1997). 
In HE, astroglial GS pathway is saturated by excess ammonia while its activity is 
further limited by oxidative and nitrosative stress developed due to hyperammonemia 
(Bobermin et al., 2015). As a result, this alters the efficacy of the astroglial 
glutamate-glutamine shuttle, causing a significant increase in intracellular glutamine 
and therefore glutamate, which then leads to an increase in release and extracellular 
glutamate (from neurons). 
 
Due to my interest in hemichannels and the parallel work described in Chapter 3, 
0Ca2+-aCSF, a common stimulus used to increase hemichannel permeability was 
applied but had no effect on glutamate release in cortical slices of BDL or HA 
animals. Interestingly, hypoxia, which is also known to increase the permeability of 
astrocytic hemichannels (Orellana et al., 2010), resulted in a significantly higher 
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glutamate release in the BDL and HA animals compared to healthy controls. 
However, this observation is unlikely to be due to altered activity of hemichannels, 
since Chapter 3, has already provided evidence of an impaired hemichannel 
functionality in the cortex of HE animals.  
 
While there is evidence depicting that astroglial glutamate reuptake is altered in 
hyperammonemic conditions, resulting in increased extracellular concentrations of 
glutamate (Chan et al., 2000, Norenberg et al., 1997), the expression of GLT-1 and 
GLAST was not altered in animal models of HE used in this study.  
 
Certain ions are essential for the correct function of glutamate transporters 
(Vandenberg and Ryan, 2013). Glutamate can therefore be transported in an 
outward direction when extracellular Na+/intracellular K+ decreases and intracellular 
Na+/extracellular K+ increases. During severe ischemia, the activity of the Na+/K+ 
ATPase is markedly supressed and the ionic gradient of Na+ (extracellular [Na+]) 
decreases resulting in reversal of astrocytic and neuronal glutamate transporters.  
Interestingly, in the BDL animals a hypoxic cerebral environment has been shown 
(Chapter 2), which could be resulting in the stated phenotype of ionic imbalance and 
transporter reversal. During the in vitro slice experiments, the oxygenation level at 
rest is expected to be similar. However, the reversal of the transports could persist 
resulting in the reported phenotype. Furthermore, the application of the hypoxic 
stimulus could be exacerbating this, resulting in more glutamate release than the 
already high basal concentration. Interestingly, co-transport of Na+ and glutamate 
via reversed glutamate transporters (during ischemia), contributes to the 
	 120	
suppression of the reversed Na+/Ca+ exchanger-induced rise in [Ca2+]i by 
maintaining Na+ gradient across astrocytic plasma membranes, contributing to the 
survival of astrocytes (Kosugi and Kawahara, 2006).   
 
Finally, high ammonia concentration may lead to a reduction in transmembrane 
electrochemical gradients of Na+ and H+ (usually changes are minor), which impair 
the driving force of astrocytic glutamate transporters, inhibiting glutamate uptake 
(Bobermin et al., 2015, Kelly et al., 2009). Additionally, a recent study by Rangroo 
Thrane et al., (Rangroo Thrane et al., 2013) reported that ammonia results in an 
increase in extracellular K+ which in combination with external acidification 
accompanied by the elevated ammonia concentrations, would greatly reduce 
glutamate transport.  Thus, significant available evidence suggests that ammonia 
plays a key role in altering the glutamate transporter activity (but not expression), 
and in triggering elevations in extracellular glutamate concentrations. This 
hypothesis is strongly supported by the significant improvement in glutamate 
concentration back to normal levels, observed in the brains of animals that have 
been treated with the ammonia-lowering agent OP. 
 
To conclude the results of experimental studies described in this Chapter 
demonstrate that HE is associated with significant changes in the extracellular 
concentration of glutamate in the cerebral cortex, with ammonia playing the key role 
in mediating this dysfunction.  
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Chapter 5: Impaired brain glymphatic flow in a rodent model of 
chronic liver disease with minimal hepatic encephalopathy 
 
5.0  Introduction 
 
The mechanisms underlying the pathogenesis of HE in patients with cirrhosis are not 
completely understood. The data available in the literature suggest that noxious 
substances and metabolites such as lactate, glutamate, bile acids and drugs 
accumulate in the brain of HE patients (Weiss et al., 2016). The currently prevailing 
hypothesis proposes that this occurs due to the metabolic and signalling defects 
induced by hyperammonemia, inflammation and alterations in BBB function 
(Shawcross et al., 2010, Hadjihambi et al., 2017).  
 
In the periphery, the lymphatic system is responsible for ISF clearance, a critical 
mechanism of maintaining tissue homeostasis. Metabolic rate of the brain is very 
high, accounting for ~20% of body energy expenditure. Although neuronal function is 
exquisitely sensitive to alterations in the extracellular environment, until recently, the 
brain was believed to be devoid of the lymphatic drainage/clearance system. Recent 
studies identified a brain-wide paravascular pathway that facilitates the efficient 
clearance of various molecules, including toxic interstitial proteins, lactate and others 
(Iliff et al., 2013a, Iliff et al., 2012). Subarachnoid CSF recirculates through the brain 
parenchyma along the paravascular spaces surrounding penetrating arteries, 
exchanging with the surrounding ISF, facilitating the clearance of interstitial solutes 
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via convective bulk flow. ISF is then cleared along paravascular spaces surrounding 
large caliber cerebral veins, which reach the recently discovered CNS lymphatic 
vessels (Louveau et al., 2015) and eventually enter systemic circulation. This 
pathway has been termed the “glymphatic system”, due to its dependence on glial 
water channels and its clearance function similar to that of the lymphatic system. In 
addition to clearing the brain, it also contributes to the distribution of growth factors, 
neuromodulators, carrier proteins and other solutes within the brain (Kress et al., 
2014). Failure of the glymphatic system may have critical adverse consequences 
and has been linked to the pathogenesis of neurodegenerative disease(s) (Iliff et al., 
2012, Peng et al., 2016).  
 
Experimental studies described in this Chapter tested the hypothesis that the 
glymphatic clearance mechanisms are impaired in cirrhosis, potentially contributing 
to the development of neurochemical phenotype observed in HE. 
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5.1  Material and methods 
 
All the experiments were performed in accordance with the Animals (Scientific 
Procedures) Act 1986 (ASPA) revised according to the European Directive 
2010/63/EU and the UK Home Office (Scientific Procedures) Act (1986) with project 
approval from the Institutional Animal Care and Use Committee.  
 
5.1.1 Animal models  
 
Male Sprague-Dawley rats (body weight ~350-400g) were obtained from a 
commercial supplier (Charles Rivers Laboratories, Inc.). 
 
BDL surgery: 16 rats underwent BDL surgery as described in detail in section 2.1.1. 
 
Blood and brain tissue were collected under terminal isoflurane anaesthesia. Plasma 
biochemistry was performed using a Cobas Integra II system (Roche Diagnostics). 
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5.1.2 Dynamic Contrast-Enhanced MRI 
 
The MRI experiments were conducted in collaboration with Dr. Ian Harrison (CABI, 
UCL), who helped with image acquisition and analysis. 
 
I. Surgical Preparation 
 
28 days after the surgery, 5 Sham-operated and 5 BDL rats were anaesthetized with 
5% isoflurane in pure oxygen for induction, followed by 2% isoflurane in oxygen for 
maintenance, and positioned in a stereotaxic frame with the head flexed to 50°. A 
midline incision was made at a midpoint between the skull base and the occipital 
margin to the first vertebrae. The underlying muscles were parted to expose the 
atlanto-occipital membrane and dura mater overlaying the cisterna magna. An 
intrathecal 24-gauge infusion catheter (0.7 x 19 mm, B|Braun, Melsungen, Germany) 
was advanced 1 mm into the cisternal space. The cannula was sealed and anchored 
in place using superglue and fast setting resin (Araldite) and the needle was then 
removed without depressurising the system. It was then attached to polyethylene 
tubing (0.4 mm x 0.8 mm, Portex) and a 100 µL glass Hamilton syringe connected to 
a microinfusion pump (PHD 2000 syringe pump, Harvard Apparatus, Cambridge, 
UK), which were all prefilled with low molecular weight paramagnetic contrast agent 
Magnevist® (21 mM Gd-DTPA, MW 938 Da; Schering Health Care Ltd., in saline 
solution).  
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II. MR Image Acquisition 
 
Following surgery, animals were transferred to an MRI compatible cradle with head 
held prone and a snout mask positioned to deliver 1.5% isoflurane in oxygen. Core 
temperature and respiratory rate were monitored using a rectal probe and pressure 
pad respectively (SA Instruments). Rats were maintained at 37°C using heated 
water tubing and feedback loop controlled warm air delivery system (SA 
Instruments). Respiratory rate was maintained between 70 and 100 breaths per 
minute by incrementally adjusting isoflurane dose. All imaging was performed with a 
9.4T VNMRS horizontal bore MR scanner (Agilent Inc., Santa Clara, California, 
USA). A 72 mm inner diameter volume coil (Rapid Biomedical, Rimpar, Germany) 
was used for radiofrequency (RF) transmission and signal was received using a 4-
channel array head coil (Rapid Biomedical). A 3D T1-weighted gradient echo 
sequence was employed to detect the motion of the Gd-DTPA with parameters: TR 
= 15 ms, TE = 3.4 ms, flip angle = 15°, NA = 3, FOV = 1.5 × 3.0 × 2.6 cm, scanning 
time = 12 min, acquisition matrix size of 128 × 128 × 128, yielding an image 
resolution of 0.12 × 0.23 × 0.20 mm. A baseline scan was acquired prior to 
intrathecal infusion of Gd-DTPA via the pre-implanted catheter (80 µl at 1.6 µl/min, 
total time 50 min). MR images were continually acquired throughout and after 
intrathecal infusion for a total time of 144 min. At the end of the experiment the 
animal was euthanized by sodium pentobarbital overdose (200 mg/kg).  
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III. Image Processing and Analysis  
 
For presentation of images, a difference image was calculated for each time point 
using the following expression:  
                              𝐷(𝑖, 𝑗, 𝑘)  =  [𝐼(𝑖, 𝑗, 𝑘) –  𝐵(𝑖, 𝑗, 𝑘)] 
Where D is the difference image, I is the time series image post Gd-DTPA infusion, 
B is the average baseline image, and (i, j, k) represent the voxel position. Signal 
intensity measured on the T1 weighted MR images over time in preselected 
anatomical areas were used to obtain intensity measurements. Both the T1-weighted 
averaged baseline images and the contrast-enhanced T1-weighted MR images were 
used to anatomically guide placement of 3D ROIs and extract volumes. The intensity 
signal for each ROI on each time point image was extracted and expressed as a % 
change from the average baseline image.   
 
5.1.3 Intracranial pressure measurements 
 
In a separate group of BDL (n=6) and Sham-operated (n=8) animals (4-weeks after 
the surgery), resting ICP was determined. Under general anaesthesia (5% isoflurane 
in pure oxygen for induction, 2% isoflurane in air for maintenance), the femoral artery 
was cannulated for blood pressure measurements. The rats were then positioned in 
a stereotaxic frame with the head flexed to 50° and a midline incision was made at a 
midpoint between the skull base and the occipital margin to the first vertebrae. The 
underlying muscles were parted to expose the atlanto-occipital membrane and dura 
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mater overlaying the cisterna magna. A 23-gauge needle attached to a cannula 
connected to a pressure transducer was inserted in the cisterna magna and the 
system was sealed immediately using surgical glue. The animal was allowed to 
recover for 15 min and the ICP was recorded. Data from previous studies have 
already shown no significant alterations in ICP during the chosen volume and rate of 
contrast agent infusion (Yang et al., 2013).  
 
5.1.4 Behavioral experiments 
 
The behavioral experiments were conducted in collaboration with Dr. Natalia Arias 
(Department of Liver and Digestive health, UCL). 
 
I. Evaluation of Prefrontal Cortex function: Spatial working memory 
 
Spatial working memory in separate groups of Sham-operated (n=5) and BDL rats 
(n=5) was evaluated in the Barnes Maze. The training consisted of one day for 
habituation in which each rat was gently placed into the escape box, which was then 
covered for 2 min. After that 2 min habituation period, the rat was placed into the 
start box located in the centre of the maze, the box was opened and the rat was 
allowed 300 s to locate the escape box. If the rat did not locate and enter the escape 
box during that allotted time, it was gently guided to and allowed to remain in the 
escape box for 15 s prior to being returned to its home cage. If the rat located the 
escape box, it was also allowed 15 s inside before being returned to its home cage. 
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The working memory training involved a paired sample task during the following six 
days of training. Each daily session consisted of two identical trials (sample and 
retention). During both trials, the escape box was in a fixed position every day, 
changing between days in a pseudorandom order. Each trial began with the start box 
positioned in the centre of the maze and the rat placed inside it. The rat remained in 
the start box for 30 s, providing a standard starting context for each trial and 
ensuring that initial orientation of the rat on the maze varied randomly from trial to 
trial. On each training trial, 11 of the 12 holes were blocked. The remaining hole 
provided access to the escape box, which was positioned on the underside of the 
maze. The ramp leading to the escape box was the same colour and texture as the 
doors blocking the holes, so that from the centre of the maze it could not be 
distinguished visually from the other 11 holes. Each rat was permitted to explore the 
maze freely. If the rat did not enter the escape box within 300 s, it was gently picked 
up by the experimenter and placed over the target hole and allowed to enter the 
escape box. The rat remained in the escape box for 15 s before it was returned to its 
home cage. The maze and escape box were cleaned carefully with a 10% alcohol 
solution to dissipate odour cues and provide a standard olfactory context for each 
trial.  
 
II. Evaluation of Hippocampal function: Spatial Reference Memory 
 
To test the reference memory in the Barnes Maze, an escape box was placed 
underneath one of the holes on the maze and remained in the same position during 
the training session for five days. Visual cues of different colours and shapes were 
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placed above four quadrants of the maze. In the acclimation period, each rat was 
placed by the edge of the escape box. The rat was gently put into the box if it had 
not entered the escape box within 1 min. During the training period, the rat was 
placed in the centre of the maze and covered by an opaque plastic box. After 15 s, 
the box was removed and the rat was allowed to walk around the maze for 3 min to 
find and enter the escape box. If the rat failed to enter the escape box within 3 min, it 
was gently guided to the box. At the end of the session, a probe test was applied in 
which the escape box was removed and the rat was introduced to the maze for 2 min 
in order to check whether the animal remembers the position of the escape box. 
Immediately after the probe test, the animals were subjected to an additional trial 
with the escape box placed in its usual position to avoid any possible interference 
with the probe test. Four trials were performed per day for five days. Time spent to 
find the target hole where the escape box used to be located (latency), distance 
travelled, speed and path efficiency were recorded and analysed by ANY-maze 
software (Stoelting Co). Path efficiency is a measure, which represents an index of 
the efficiency of the path taken by the animal to get from the starting position to the 
escape box. A value of 1 indicates perfect efficiency- the animal moved in a straight 
line- less than 1 indicates decreasing in efficiency. The maze was wiped thoroughly 
with 10% alcohol solution to avoid olfactory cues. 
 
 
 
 
	 130	
5.1.5 Statistical analysis 
 
Statistical comparisons between MR time course data from Sham-operated and BDL 
groups were performed using two-way ANOVA with Bonferroni post-hoc test. 
 
ICP recorded in Sham-operated and BDL animals was compared using a Student’s t 
test and biochemistry data was analysed using one-way ANOVA. 
 
For the neurobehavioral experiments, normality test for each group and parameter 
was performed. Statistical comparisons of data between Sham-operated and BDL 
animals were performed via two-way ANOVA with Bonferroni post-hoc test. For 
comparison of data within animal groups along training days, two-way ANOVA was 
applied followed by Tukey post-hoc test.  
 
Statistical tests were performed using GraphPad Prism (v6 for Windows, San Diego, 
CA, USA), and all data were reported as mean±SEM. Differences with p value of 
<0.05 were considered to be significant.  
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5.2  Results 
5.2.1 Biochemistry 
 
Plasma biochemistry and ammonia concentration were assessed in all groups of 
animals, showing the same changes as described in Chapter 2 (Table 2). 
 
5.2.2 Glymphatic flow evaluated using dynamic contrast-enhanced MRI 
 
Dynamic contrast-enhanced MRI was used to visualize brain-wide subarachnoid 
CSF-ISF exchange in anesthetized BDL rats (n=5), and Sham-operated control 
animals (n=5). Time course of parenchymal distribution of the paramagnetic contrast 
agent, gadolinium (Gd-DTPA) throughout the brain was assessed as a measure of 
glymphatic flow (Iliff et al., 2013a, Iliff et al., 2012). Following an intra-cisternal 
infusion of gadolinium, serial acquisition of T1-weighted MR images was performed 
(Figure 28A). The integrity of the skull was confirmed by monitoring the temporalis 
muscle for the presence of gadolinium, to ensure a sealed and intact system, which 
is essential for the glymphatic flow (Figure 29E). 
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Figure 28: Impaired contrast agent penetration in the brain of animals with HE.  A. 
Representative images of dynamic contrast-enhanced MRI of Sham-operated and BDL 
animals. Pseudocolour scaling illustrates distribution of gadolinium throughout the brain over 
the 144 min of the recording, with the BDL brain showing reduced contrast agent and 
therefore glymphatic inflow in rostral areas. B. Summary data illustrating resting intracranial 
pressure (ICP) in Sham-operated and BDL animals. Summary data showing MR contrast 
intensity changes in C. the olfactory bulb D. the prefrontal cortex and, E. the hippocampus of 
Sham-operated and BDL rats. Inset: Schematic drawing illustrating the brain regions of 
interest. Shading indicates period of contrast agent infusion. p values indicate the level of 
significant differences between the sham-operated and BDL groups. 
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In order to assess the ability of the brain to distribute the infused contrast agent, the 
brain was compartmentalized (on analysis) and the quantification of signal intensity 
vs. time of inflow was compared between the experimental (BDL) and control (Sham-
operated) animal groups. CSF filled compartments, including the aqueduct, third and 
lateral ventricles, showed no significant differences in flow between Sham-operated 
and BDL animals (Figure 30A-D). Similarly, time-course of the parenchymal 
distribution of the contrast agent in the striatum (p=0.4), midbrain (p=0.7), caudal 
cortex (p=0.1), thalamus (p=0.06) and hypothalamus (p=0.2) was not different 
between the two animal groups (Figure 29A-D, F).  
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Figure 29: Unchanged contrast agent penetration in the striatum, caudal cortex, 
midbrain, thalamus, and hypothalamus of animals with HE.  A. Intensity (% change from 
the baseline) vs. time plots of contrast agent penetration in the striatum showing no 
difference between Sham-operated and BDL rats. B. Intensity (% change from baseline) vs. 
time plots of contrast agent penetration indicating no difference in the caudal cortex of 
Sham-operated and BDL rats. C. Intensity (% change from baseline) vs. time plots of 
contrast agent penetration indicating no difference in the midbrain of Sham-operated and 
BDL rats. D. Intensity (% change from baseline) vs. time plots of contrast agent penetration 
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indicating no difference in the thalamus of Sham-operated and BDL rats. E. Intensity (% 
change from baseline) vs. time plots of contrast agent penetration in the temporalis muscle 
of Sham-operated and BDL rats acting as negative control. Lack of contrast agent in the 
temporalis muscle represents a sealed system and no CSF leakage due to the cannula 
implantation. F. Intensity (% change from baseline) vs. time plots of contrast agent 
penetration indicating no difference in the hypothalamus of Sham-operated and BDL rats. 
Grey shading indicates period of contrast agent infusion. p values indicate the level of 
differences between the Sham-operated and BDL groups. 
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Figure 30: Contrast agent inflow in CSF filled compartments (aqueduct, lateral 
ventricles and third ventricle) and volumes of select brain regions are not altered in 
HE. A. Intensity (% change from baseline) vs. time plots of contrast agent penetration 
indicating no difference in the aqueduct of Sham-operated and BDL rats. B. Intensity (% 
change from baseline) vs. time plots of contrast agent penetration indicating no difference in 
the lateral ventricles of Sham-operated and BDL rats. C. Intensity (% change from baseline) 
vs. time plots of contrast agent penetration indicating no difference in the 3rd ventricle of 
Sham-operated and BDL rats. Grey shading indicates period of contrast agent infusion. D. 
Summary data illustrating volume (mm3) of the brain regions of interest obtained from 3D 
ROI measurements of contrast-enhanced MR images from Sham-operated and BDL 
animals, with no significant differences reported. p values indicate the level of differences 
between the sham and BDL groups. 
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Parenchymal penetration of the contrast agent in the olfactory bulb (p<0.0001) and 
prefrontal cortex (p=0.01) was dramatically reduced in BDL rats compared to Sham-
operated animals, indicating that the efficacy of glymphatic flow in these areas is 
compromised (Figure 28C-D). In contrast, facilitated inflow of contrast agent was 
observed in the hippocampus (p=0.03) of BDL rats (Figure 28E), further suggesting 
that glymphatic flow is altered in this model of mHE.  
 
5.2.3 Measurement of intracranial pressure and volume of the brain regions of 
interest in Sham-operated and BDL animals  
 
Impairment of parenchymal contrast agent penetration could be due to altered ICP in 
BDL animals. Therefore, volumes of select brain regions obtained from 3D ROI 
measurements of contrast-enhanced MR images (Figure 30D) and recorded ICP 
from the cisterna magna (Figure 28B) were next determined in Sham-operated (n=8) 
and BDL (n=6) animals.  
 
The results obtained demonstrated that the observed contrast agent inflow 
impairment cannot be attributed to altered pressure in the brain, as the volumes of 
brain regions (p>0.05 for all regions) and the ICP recorded from the cisterna magna 
(p=0.7) were not different between Sham-operated and BDL animals.  
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5.2.4 Evaluation of Prefrontal Cortex function: Spatial working memory 
 
To determine the functional consequences of altered glymphatic flow, an array of 
behavioral and cognitive tests were performed in BDL (n=5) and Sham-operated 
(n=5) animals. The prefrontal cortex and hippocampus are involved in learning and 
memory (Damasio, 1989, Squire et al., 1992). Prefrontal cortex is critically involved 
in cognitive functions such as working memory, a process of maintaining an active 
representation of information available for use, as well as organization and planning 
of responses (Fuster, 1990). Testing spatial working memory in the Barnes Maze 
was then used to assess the function of prefrontal cortex. While there was no 
difference between the animal groups in time required to reach the escape box 
during the sample trial (p=3) (training on the day to learn the new location of the 
escape box), significant differences between the BDL and Sham-operated animals in 
the retention trial (p=0.02) were recorded (Figure 31A-B). These data suggest that 
the BDL animals are unable to retain an active representation of information 
indicating an impairment of the prefrontal cortex function.  
 
 
 
 
 
 
	 139	
 
 
Figure 31: Cognitive/behavioral deficits in HE. A. Summary data illustrating time latency 
required to reach the escape box in the working memory task in Sham-operated and BDL 
rats. Summary data illustrating B. retention latency in the working memory task, C. latency, 
in the spatial reference memory task, D. speed of animal during the reference memory task, 
E. distance travelled during the reference memory task and F. path efficiency from the 
starting point to the escape box during the reference memory task comparing sham and BDL 
rats. p values indicate the level of significant differences between the sham-operated and 
BDL groups. For within group comparison *p<0.05, ***p<0.001. 
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5.2.5 Evaluation of Hippocampal function: Spatial Reference Memory 
 
As the hippocampus is important in the acquisition of spatial reference memory (Li et 
al., 2013), further tests to assess its function were performed in the Barnes Maze. 
Although no differences were observed in escape latencies between BDL and 
Sham-operated animals (p=0.2), the control group showed a progressive and 
significant improvement in the task acquisition during the training days (p=0.01), 
which was not observed in the BDL animals (p>0.05) (Figure 31C). This indicates 
the inability of BDL animals to learn how to use the reference cues in order to 
reach the escape box, suggesting potential impairment of hippocampal function. 
There were no differences in the speed (p=0.4) and distance travelled (p=0.4) 
between the two groups of animals, suggesting that the observed differences in 
latency were not due to the potential locomotor deficiency in the BDL rats (Figure 
31D-E). Moreover, the learning ability of Sham-operated, but not of BDL animals 
was observed through the significant decrease in distance covered (within the 
group, p<0.001), which was also reflected in the increase of path efficiency 
(p=0.01) along training days (Figure 31F). These results demonstrate a functional 
correlate to the observed alteration in glymphatic flow in the hippocampus.  
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5.3  Discussion 
 
Many diseases, mainly neurodegenerative, are associated with accumulation of 
cellular waste products (such as by-products of cellular respiration). Intracellular 
proteasomal degradation and autophagy are considered the principal means for 
removing proteins in the CNS and the dysfunction of these processes has been 
associated with neurodegeneration (Nedelsky et al., 2008). Yet, many cytosolic 
proteins are released into the interstitial space of the brain, suggesting that effective 
disposal routes should exist in order to eliminate waste. Preliminary evidence exists 
showing bile acid accumulation in the CSF (not included in this thesis) and excessive 
release of glutamate in the brain of rodent models of HE (Chapter 4), which add to 
the human data indicating the accumulation of many noxious substances and 
metabolites in the ISF and CSF collected from the brain of HE patients (Weiss et al., 
2016). These data therefore points to a possible impairment of the glymphatic flow, 
which results in the lack of brain clearance observed.  
 
This study demonstrates impaired CSF penetration and parenchymal clearance of 
the contrast agent in the olfactory bulb and prefrontal cortex of HE rats, indicating a 
clear dysfunction of the glymphatic clearance system in an animal model of mHE. 
The reasons underlying increased contrast agent inflow in the hippocampus are 
unclear at the moment, but may be due to cell loss/neurodegeneration, also seen in 
animal models of Alzheimer’s disease or regional glial alterations that may occur in 
HE (Hernandez-Rabaza et al., 2016). Cytotoxic oedema and energy depletion, which 
are known features of HE, enhance glymphatic CSF influx while suppressing ISF 
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efflux (Thrane et al., 2014) may also contribute to the increased contrast inflow in the 
hippocampus. The data showing memory deficits in this model of HE provide a 
functional correlate for these findings indicating impairment of the prefrontal cortex 
function as well as a potential derangement in hippocampal-prefrontal cortex 
connections. The pathophysiological mechanisms underlying impaired glymphatic 
flow reported here are unclear. However, several factors, some known to be 
deranged in HE, such as reactive astrogliosis (Iliff et al., 2014), hemichannel 
dysfunction (Hadjihambi et al., 2017), loss of perivascular astroglial AQP4 water 
channel polarization (Kress et al., 2014), altered neuronal activity (Thrane et al., 
2014), arterial pulse-pressure (Iliff et al., 2013b), CNS inflammation (Erickson et al., 
2012) may play a role. Interestingly, many of these factors are prominent during 
other diseases (Kress et al., 2014) and could represent important therapeutic targets 
to restore paravascular CSF-ISF exchange.  
 
Connexin hemichannel dysfunction in animal models of HE has been reported in 
Chapter 3. These porous channels are vastly expressed on astrocytes and allow the 
(controlled) passage of various ions and molecules as well as water (Beyer and 
Berthoud, 2014). Impairment of the opening of these channels, as seen in HE, can 
potentially compromise water transport across astrocytes and therefore convective 
bulk flow, which will then compromise the process of CSF-ISF exchange, resulting in 
the reported glymphatic flow impairment.   
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Volume homeostasis of cells requires energy in order to be maintained. Energy 
depletion, (evidence of potential neuronal energy deficit in HE reported in Chapter 3) 
(Hadjihambi et al., 2017), can cause brain cell swelling termed cytotoxic oedema. 
From extensive studies on HE rodent models, it is known that ammonia plays a 
direct role in the development of this oedema and it is mainly observed in astrocytes, 
although this is mild in mHE. Astrocytic end-feet interpose a high-resistance barrier 
to fluid-solute flux between paravascular and interstitial compartments. Pericyte and 
microglial processes are also scattered in between the vascular wall and astrocyte 
end-feet, which creates a filter size of glial barrier large enough for nearly all-
mammalian proteins (~35kDa and diameter 2-3 nm, including serum albumin 
~70kDa and 4-6 nm diameter). Astrocytic swelling (extending to the end-feet) can 
therefore largely interfere with the clearance of the brain by obstructing the 
paravascular CSF-ISF exchange and solute clearance. 
 
An interesting idea reported by Thrane et al (Thrane et al., 2014), was that GJ 
connections between astrocytes might rapidly distribute Na+-influx across the glial 
syncytium (Ezan et al., 2012, Rose and Ransom, 1997). Na+ and Cl- redistribution 
would in turn make ISF slightly hypo-osmolar relative to CSF (Ishimaru et al., 1993), 
which would build an osmotic ISF-CSF gradient that in theory will pull CSF into the 
ISF compartment. Results of the experiments described in Chapter 3 demonstrated 
functional hemichannel dysfunction in the cerebral cortex of BDL animals. This 
dysfunction could also extend to the GJ level, preventing the distribution of these 
ions and therefore the development of an osmotic gradient, which will consequently 
diminish the efficacy of the glymphatic clearance pathway as demonstrated in this 
Chapter. 
	 144	
In conclusion, this study provides the first experimental evidence of impaired 
glymphatic clearance in HE.  
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Chapter 6: General Discussion and Summary 
 
The experimental studies described in this thesis aimed to determine whether during 
HE, chronic exposure to elevated ammonia concentrations interferes with cerebral 
oxygenation, compromises lactate transport between cells and affects uptake of 
neurotransmitters. Additionally, experimental studies were aimed to test the 
hypothesis that HE impairs glymphatic clearance mechanisms, either as a cause or 
a consequence of the disease, which contributes to the cognitive impairment. HE is a 
serious syndrome, which has detrimental effects on the socioeconomic status and 
quality of life of patients. It is, therefore, necessary to have a very clear and in depth 
understanding, of how the contributing pathogenic factors involved, affect the brain 
on the molecular, membrane, cellular and neuronal/astroglial network level. This 
study used contemporary neuroscience methods applied in carefully designed and 
executed experiments conducted (in vivo and in vitro) in animal (rat) models. 
Collectively, this thesis demonstrates that in animal models of HE, chronic 
hyperammonemia compromises cerebral oxygenation without affecting 
cerebrovascular reactivity and it is associated with cortical hemichannel dysfunction, 
impaired lactate release, as well as significant increases in cortical extracellular 
glutamate concentrations, which is exacerbated under hypoxic conditions. Finally, 
glymphatic function is altered at discrete regions of the brain, which aligns with 
specific cognitive impairments observed in these animals.  
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Experiments described in Chapter 2 were designed to determine whether cerebral 
oxygenation is impaired in HE and, if so, explore the potential underlying 
mechanisms. The data obtained demonstrate that HE is associated with reduced 
brain tissue PO2, which is independent of systemic hypotension. Ammonia lowering 
treatment prevented this decrease in cerebral PO2 suggesting that ammonia plays 
a key role in this phenotype. The exact mechanism leading to the compromised brain 
oxygenation in HE is still unclear, although the results of this thesis in combination 
with the current literature suggest that ammonia may act by reducing brain metabolic 
activity, as well as by indirectly increasing vascular tone with secondary effects on 
CBF.  
 
These findings provide the first insights into an ammonia-triggered mechanism 
involving compromised CBF, which results in decreased brain tissue oxygenation, 
and is hypothesised to contribute to the pathogenesis of HE. Further experiments 
are required to unravel the exact mechanism. CBF will be further investigated in an 
MRI study, examining baseline perfusion, effectiveness of ACTZ and sildenafil in 
increasing CBF, as well as integrity of neurovascular coupling in animal models of 
HE. Additionally, cognitive tests will be performed in BDL and Sham-operated 
animals treated with ACTZ or vehicle in order to assess the role of reduced cerebral 
oxygenation in cognitive decline observed in animal models of HE. Finally, the role of 
pericytes have yet to be investigated in the field of HE and it will be an important 
area of study due to the increasing evidence pointing towards their active control of 
the capillary blood flow and CBF regulation in health and disease.   
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Having established the presence of compromised cerebral oxygenation in HE, the 
experiments described in Chapter 3 were designed to determine whether chronic 
ammonia exposure alters brain extracellular lactate concentration and, if so, study 
the potential underlying mechanisms.  
 
It was found that HE is associated with a significant reduction in both tonic and 
hypoxia-induced lactate release in the cerebral cortex, which was normalised by 
ammonia-lowering treatment. Cortical dye loading experiments revealed 
hemichannel dysfunction in HE with improvement following OP treatment, while the 
expression of key connexins was unaffected. These results demonstrate that HE is 
associated with cortical hemichannel dysfunction, with ammonia playing a key role. 
The data provide evidence of a potential neuronal energy deficit due to impaired 
hemichannel-mediated lactate transport between astrocytes and neurons as a 
possible mechanism underlying pathogenesis of HE. 
 
Subsequent experiments described in Chapter 4 were designed to test the 
hypothesis that chronic ammonia exposure may also alter the extracellular 
concentration of neurotransmitters. To test this hypothesis glutamate concentrations 
were assessed in the cerebral cortex of BDL and Sham-operated animals. The data 
obtained demonstrate an increase in tonic glutamate concentration in the cortex (but 
not the cerebellum) of BDL and HA rats compared to Sham-operated controls. 
Evidence suggests that ammonia plays a key role in compromising the glutamate 
transporter activity and therefore glutamate uptake, but not the expression of the 
transporters as seen by the unaltered expression of GLT-1 and GLAST in the animal 
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models of HE used in this study. The hypothesis of ammonia mediating this change 
is strongly reinforced by the significant improvement in glutamate concentration back 
to normal concentrations, observed in the brains of animals that have been treated 
with ammonia-lowering agent. Thus, these results demonstrate that HE is associated 
with significant changes in the extracellular concentration of glutamate in the 
cerebral cortex, with ammonia playing the key role.  
 
Having established the ammonia-mediated increase in extracellular glutamate 
concentration, the experiments described in Chapter 5 were aimed to evaluate 
whether the glymphatic flow and therefore clearance is impaired in HE, and if so, 
determine whether the affected brain regions correlate with cognitive alterations. In 
this study, a dynamic contrast-enhanced MRI technique was used to assess the 
efficacy of the glymphatic clearance, which facilitates clearance of solutes from the 
brain. Discrete brain regions (olfactory bulb, prefrontal cortex and hippocampus) of 
altered glymphatic flow were identified, which aligned with behavioral deficits. 
Although the underlying pathophysiological mechanisms remain unclear, this study 
provides the first experimental evidence of impaired glymphatic clearance in HE. 
 
Reduced efficacy of glymphatic clearance has been seen in several diseases 
including Alzheimer as well as during normal aging (Iliff et al., 2012, Peng et al., 
2016). In Alzheimer’s disease there is a gradual build-up of amyloid beta peptides in 
the brain parenchyma, likely due the impairment of glymphatic clearance. This leads 
to impaired neurovascular coupling inducing decrease in CBF, BBB disruption and 
altered vascular structure (Kyrtsos and Baras, 2015). Similarly, reduction in ISF flow 
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as a consequence of aging, induces vascular abnormalities such as compromised 
vascular tone and vessel wall pulsatility (Kyrtsos and Baras, 2015, Kress et al., 
2014). This suggests that an impaired glymphatic pathway could be responsible for 
the phenotypes reported throughout this study and therefore the progression of HE. 
However, since the glymphatic impairment in HE is a very recent observation, not 
enough evidence exists regarding the timeline and sequence of events (glymphatic 
impairment resulting in altered neurochemical phenotype or visa versa). 
Nevertheless, it is possible that this is a result of hyperammonemia (a consequence 
rather than a cause) and could be reversed by ammonia-lowering treatment(s). 
 
Potential areas for further investigation 
 
It is well known that sleep improves memory and maintains metabolic balance of the 
body, while sleep deprivation impairs cognitive performance and is a common cause 
of seizures. A recent study has proposed that during sleep glymphatic clearance is 
facilitated while its efficacy is suppressed during wakefulness (Xie et al., 2013). This 
suggests that one of the major functions of sleep could be to promote glymphatic 
clearance of metabolic waste products produced during wakefulness. Interestingly, 
CLD and HE conditions are always accompanied by dyssomnia (Bajaj et al., 
2011),(Liu et al., 2015).  
 
mHE patients suffer from poor sleep quality, take longer to fall asleep, exhibit lower 
sleep efficiency and show daytime functional disturbances (Liu et al., 2015). Aside 
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from anxiety and depression other psychiatric factors tend to have a negative impact 
on sleep quality, which results in a vicious cycle and further health deteriorations. 
 
A study by Lundgaard et al., (Lundgaard et al., 2016) has proposed that the 
glymphatic system is responsible for state-dependent changes in brain 
lactate concentration with lactate being high during wakefulness and declines within 
minutes of sleep. The authors have suggested that brain lactate is a good biomarker 
of sleep-wake cycle and increases further during sleep deprivation, since brain 
extracellular lactate concentration is inversely correlated with glymphatic-lymphatic 
clearance. Based on this observation and the hypothesis that lactate may have an 
excitatory effect (through the activation of neurons releasing norepinephrine) (Tang 
et al., 2014), it would be interesting to investigate the possibility that impairment of 
glymphatic pathway in HE, results in lactate accumulation, which exerts an excitatory 
effect on arousal-promoting neurons and therefore prevents sleep.  
 
The experimental plan proposed for investigating this hypothesis is as follows: Sleep 
activity will be monitored in Sham-operated and BDL animals through 
electromyogram (EMG) recordings achieved by bilateral placement of wires in both 
neck muscles. During sleep EMG activity decreases while wakefulness is 
characterised by significant increase in EMG activity. If more accurate monitoring of 
sleep is required then an electroencephalogram will also be recorded. A decrease in 
lactate release during HE was reported in Chapter 3. This could still result in a 
significant extracellular accumulation of if the glymphatic pathway is impaired.  
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Once the sleeping pattern of animals is established, the effect of L-lactate can be 
investigated. Implantation of EMG electrodes will be repeated in another group of 
animals, in combination with viral microinjection, which mediate the conversion of L-
lactate to D-lactate. D-lactate, is the stereoisomer of L-lactate and is believed to 
antagonize its actions (Gibbs and Hertz, 2008). This will allow us to study the 
effect of lactate accumulation (proposed to be due to a glymphatic impairment) on 
the sleeping pattern of animals with HE. If an improvement in sleep is observed, 
further glymphatic system manipulations can be applied in these animals (e.g. 
cisterna magna puncture) to ensure that the observed effect depends on the 
glymphatic activity. Therefore, this study might be able to propose alternative 
treatments for HE patients who suffer from sleep disturbances and cognitive 
decline.   
 
Finally, another possible area of study would be the investigation of astrocytic 
volume and interstitial space during sleep and wakefulness. Xie et al., (Xie et al., 
2013) have shown that during sleep the interstitial space increases, improving the 
efficiency of glymphatic clearance, as a result of astrocytic shrinkage at sleep. It 
would therefore be interesting to investigate whether in HE the “swollen” 
astrocytes or the interstitial space are able to adapt their volume during sleep. 
This could be another factor contributing to the impaired glymphatic activity and 
sleep disturbances observed in HE.  
 
To conclude, the data obtained in this study provide the first evidence of a critical 
pathophysiological role of ammonia in inducing neuronal energy deficit in HE due to 
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impaired cerebral oxygenation, compromised hemichannel-mediated lactate 
transport between astrocytes and neurons and affected glymphatic clearance. 
Additionally, while most literature in the field is focused on astrocytes and their 
morphological alterations during the disease, it has been unclear what this means in 
terms of their functionality. During this thesis, data indicated a functional contribution 
of astrocytes in the development of the disease and introduced the important 
concept of an altered astrocyte-neuron communication, which has not been looked 
at before in HE. While studies of other factors potentially involved in the progression 
of the disease, such as inflammation, have been beyond the scope of this study, 
they are not excluded as possible contributors. However, the results obtained 
indicate reversible phenotypes when treated with an ammonia-lowering agent (such 
as OP), which holds great therapeutic potential in the field of HE. 
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